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“I Hear And I Forget. I See And Remember. I do, And I Understand.” 
By Confucius 
(As Palavras convencem, mas os exemplos arrastam/Actions speak louder than words) 
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1.1 DIABETES MELLITUS 
Currently, diabetes mellitus affects 415 million people around the world, and this number is 
expected to increase to 642 million by 2040 (http://www.idf.org/). This metabolic disorder of 
multiple etiologies characterized by chronic hyperglycemia is the most common cause of 
nephropathy, retinopathy, neuropathy, and cardiovascular disease leading to heart attack and 
stroke (http://www.who.int/diabetes/en/). Diabetes mellitus is the fourth leading cause of death 
in most developed countries, and the disease diminishes not only the quality of life but also life 
expectancy [1]. While type 2 diabetes (T2D) is the most common form of diabetes, type 1 
diabetes (T1D), the main focus of this thesis and previously classified as insulin-dependent 
diabetes mellitus and juvenile-onset diabetes, accounts for over 90% of diabetes in young 
people aged under 25 years and results from a selective autoimmune-mediated destruction of 
insulin-producing beta cells contained in the islets of Langerhans in the pancreas [2–5]. The 
incidence of T1D is increasing worldwide especially in the last three decades and in children 
less than five years of age, but the roots of this steady rise are poorly documented [6,7]. Up to 
date, the standard of care for all T1D patients but also for 25% of T2D patients is lifelong 
exogenous insulin administration as basal-bolus therapy either with several daily injections or 
continuous subcutaneous insulin infusion. Despite impressive improvements in insulin analogs, 
insulin pumps, and glucose sensors, current insulin therapies still do not match the insulin 
secretory profiles of endogenous pancreatic beta cells, and all pose risks of suboptimal glycemic 
control, hypoglycemia, and ketoacidosis, in particular in children and adolescents. Therefore, 
in patients with recurrent hypoglycemic episodes despite optimal insulin therapy and chronic 
macro- and microvascular complications, alternative approaches are required [5,8,9]. 
 
1.2 TYPE 1 DIABETES AS AN AUTOIMMUNE DISEASE 
T1D is a T-cell-mediated autoimmune disease that induces selectively loss of functional beta-
cell mass in the endocrine pancreas, leading to absolute insulin deficiency [10]. The destructive 
process of the beta cells by the immune system in the patients starts many years before clinical 
detection and presentation of the first symptoms of the disease. What triggers the autoimmune 
destruction of the beta cells in T1D remains unidentified, but genetic and environmental factors 
are believed to act together to precipitate the disease. Moreover, our understanding of the 
immunopathogenesis of the disease has increased tremendously during the last years and points 
towards major imbalances between multiple regulatory and effector immune mechanisms. 
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1.2.1 Genetics 
The primary risk factor for T1D is genetic (reviewed in [11]) as evidenced by the strong disease 
concordance in monozygotic twin pairs (≥50%)[12]. Moreover, kids born in T1D families have 
different lifespan risks depending on whether the mother (3%), father (5%) or a brother/sister 
(8%) has the disease [13]. Four decades of studies have shown that immune genes, especially 
those that encode for the human leukocyte antigen (HLA) system, the major histocompatibility 
complex (MHC) proteins in humans, confer the strongest genetic risk for T1D [14]. The genes 
that encode the HLA molecules, the most polymorphic known in the human genome, are located 
on chromosome 6p21. HLA class I (i.e. HLA-A, B and C) molecules are found in almost all 
cells, while HLA class II (i.e. HLA-DR, DQ, and DP) molecules are confined to professional 
antigen-presenting cells (APCs), including macrophages, dendritic cells, and B cells, and in 
humans, activated T cells also express HLA class II. By the 1980s, the very high risk of having 
a heterozygous genotype consisting of a haplotype including HLA-DRB1*0301 on one 
chromosome and HLA-DRB1*0401 on the other (commonly referred to as HLA-DR3/4) was 
reported [15]. The combinations HLA-DR3-DQ2 (DQB1*0201) and HLA-DR4-DQ8 
(DQB1*0302) are present in 90% of T1D children [16,17], but an environmental trigger is 
usually needed to further progress to beta-cell autoimmunity (see 1.2.2). In patients harboring 
the high-risk HLA-DR3 and HLA-DR4 class II alleles, the HLA-A*0201 allele has been shown 
to confer additional risk to T1D development [18]. HLA-A*0201 is one of the most prevalent 
HLA class I alleles, with a frequency of more than 60% in T1D patients [19]. The genotype 
combining two susceptibility haplotypes contributes to the highest risk of T1D and is most 
common in kids who develop the disease at a very early age [20]. Since HLA molecules are 
known to play a role in antigen presentation, the HLA linkage and association support the 
concept that T1D has an important autoimmune element. Interestingly, islet autoantibodies (see 
1.2.3), at the time of T1D diagnosis, are known to be associated with HLA-DR-DQ haplotypes 
or alleles. Kids homozygous for HLA-DR3-DQ2 often have autoantibodies against the 65 kD 
isoform of glutamic acid decarboxylase (GAD65)(GADA) as the first autoantibody, while kids 
with the HLA-DR4-DQ8 haplotype tend to have insulin autoantibodies (IAA) as the first 
autoantibody. 
Nowadays, it is clear from genome-wide association study (GWAS) meta-analyses and single 
nucleotide polymorphism (SNP) profiling studies that also other genes confer risk to T1D 
development (e.g. the insulin (Ins) gene on chromosome 11 is associated with T1D)[21]. The 
Ins gene was identified as the second most important genetic susceptibility factor, contributing 
10% of the risk to T1D [22,23]. There is also evidence for another risk locus in human T1D, 
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which is mapped in the Il2RA region on chromosome 10p15.1 [24]. The interleukin-2 (IL2) 
receptor alpha (Il2RA, also known as CD25) encodes the α-chain of the IL2R complex and 
binds IL2 with high affinity. CD25 is expressed on T cells upon activation and also on natural 
regulatory T cells (Tregs) at baseline. Since IL2 is essential for Treg growth and survival, and 
IL2 signaling is mainly mediated by IL2RA [25], a reduction in the expression or function of 
Il2RA gene could contribute to autoimmune disease susceptibility. Two SNPs in the Il2RA gene 
were found to be significantly associated with T1D and suggested a potential role of Il2RA in 
the pathogenesis of T1D, likely involving Treg functionality [26–28]. Cytotoxic T-lymphocyte-
associated protein 4 (Ctla4) is a down-regulator of the immune response. T1D association with 
Ctla4 was noted in multiple ethnic groups, although with a variable degree of importance [29]. 
The immune regulator Ptpn22 (gene located at chromosome 1p13) was shown to be associated 
with T1D in 2004 [30]. The Ptpn22 gene encodes a protein tyrosine phosphatase important in 
down-regulation of the immune response. Since Ctla4 and Ptpn22 are also implicated in other 
autoimmune diseases including autoimmune thyroid disease [31], it supports the idea that 
similar or overlapping biological pathways for a different autoimmune disease may exist 
[32,33]. Interestingly, the susceptible T allele of the Ptpn22 SNP can be linked with IAA or 
GADA. On the other hand, the susceptible A allele of the INS SNP has linkage with IAA, but 
not with GADA, whereas the minor G allele of the Ctla4 SNP increased the risk for GADA 
positivity, yet not for IAA [34]. 
 
1.2.2 Environment 
Only environmental and lifestyle changes can clarify the steep rise in T1D incidence over the 
last three decades (reviewed in [35]). In Europe, T1D risk varies considerably in people who 
are genetically alike but separated by social and economic boundaries [36]. This hazard 
becomes more uniform in societies with the ability to travel [37]. Several hypotheses have been 
put forward, one of the most accepted is called the “hygiene hypothesis,” which relates to 
improved sanitation and postulates that fewer early infant infections and less diverse symbiotic 
gut microflora deviate the immune system towards beta-cell autoimmunity [38]. Numerous 
viruses have been implicated in T1D etiology, with enteroviruses having the strongest 
association with T1D in both animal models [39] and men [40]. Several studies suggest a role 
for innate immune system activation in this model. Direct evidence for the involvement of 
viruses in T1D comes from the injection of polyinosinic-polycytidylic acid (poly-(I:C)), a 
mimic of viral double-stranded RNA (dsRNA) that induces interferon (IFN)-α secretion, which 
triggers insulitis and diabetes in normal non-diabetic rodents [41,42]. In humans, other 
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convincing evidence of associations between viral infections and T1D risk comes from the 
congenital rubella syndrome [43]. T1D developing in congenital rubella patients has the genetic 
and immunological features of classical T1D [44]. Other viral infections especially in the 
gastrointestinal tract (e.g. rotaviruses) have been reported to be associated with the appearance 
of serum autoantibodies to islet antigens [45]. However, the role of viral infections as a cause 
of beta-cell loss in human diabetes remains to be elucidated.  
Another important environmental factor that is believed to influence T1D is diet. Several 
candidates have been described such as a short duration of breastfeeding [46,47], the feeding 
of cow’s milk proteins during the early months of infants’ life [48], and the early introduction 
of solid foods and cereals [47]. However, results of these studies must be interpreted with 
caution. 
The involvement of the gastrointestinal system in T1D etiology is suggested by differences in 
intestinal microbiota composition observed in individuals diagnosed with T1D or with evidence 
for islet autoimmunity [49–51]. In addition, proof-of-concept studies conducted in NOD mice 
provide evidence to suggest that changes in the composition of intestinal microbiota prevent or 
reduce T1D incidence [52–54]. 
Numerous studies have found associations between T1D development and vitamin D (reviewed 
in [2,55]). The host lab has a great interest in the active metabolite of vitamin D, 1,25-
dihydroxyvitamin D3, as a natural immunomodulatory molecule [56]. 1,25-dihydroxyvitamin 
D3 prevents insulitis and diabetes in NOD mice, although with serious calcemic side effects 
[57,58]. Interestingly, in mice, vitamin D deficiency predisposes to diabetes [59] while vitamin 
D supplementation prevents T1D [60]. Based on these observations, the host lab proposes that 
vitamin D deficiency should be avoided, especially in all at-risk people. 
Besides “the hygiene hypothesis” also “the beta-cell stress hypothesis” exist which suggests 
that common environmental elements such as birth weight and infant growth, toxins and 
chemical compounds, dietary deficiencies or biological stress (leading to posttranslational 
modifications (PTMs) and the generation of islet neoantigens [61–63](see 1.2.3), alone or in 
combination, exhaust and damage the pancreatic beta cells, leading to secondary beta-cell 
autoimmunity. Several questions still remain about the environmental and lifestyle influence in 
T1D. However, some observational cohort studies such as The Environmental Determinants of 
Diabetes in the Young (TEDDY) study aim to ascertain environmental determinants that may 
trigger islet autoimmunity and either speed up or slow down the progression to clinical onset in 
subjects with evidence for persistent islet autoimmunity will bring new insights 
(https://teddy.epi.usf.edu/). 
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1.2.3 Autoantibodies 
There are several islet autoantibodies and autoantigens related to T1D. In kids who are 
genetically at risk for developing T1D, the onset of T1D-related autoantibodies peaks between 
9 and 24 months of age, with IAA appearing first [64]. Indeed, the most widely used in clinic 
and research are IAA, islet cell cytoplasmic autoantibodies (ICA), and autoantibodies directed 
against the four major pancreatic islet autoantigens: GAD, protein tyrosine phosphatase IA-2A 
and its isoform IA-2b/phogrin (IA-2bA) and zinc transporter 8 (ZnT8). Recently a fifth 
autoantigen has been described: tetraspanin-7, a multipass transmembrane glycoprotein with 
neuroendocrine expression [65]. Although tetraspanin 7 autoantibodies are a marker of T1D, 
they seem to provide minor additional value to existing autoantibodies in identifying ongoing 
beta-cell destruction [66]. Other T1D-related autoantibodies have also been described but are 
difficult to measure and/or are often not sufficiently sensitive. Recently, several groups 
proposed that PTMs within the endoplasmic reticulum (ER) of beta cells under stress might 
impact on the autoantigen T-cell epitope repertoire and T1D development [61–63]. For 
example, the host lab demonstrated that citrullinated glucose regulated protein 78 (GRP78) is 
a new autoantigen in T1D in NOD mice [67]. Lately, the group of K. Haskins demonstrated 
that through transpeptidation of insulin fragments a new class of naturally occurring 
autoantigens called hybrid insulin peptides (HIPs) can be formed. The resulting peptides are 
very immunogenic not only for diabetogenic CD4+ T cells from the NOD mice but also for 
CD4+ T-cell clones isolated from the residual islets of T1D patients [68,69]. 
From all the major autoantigens only insulin is unique to the beta-cell. IAA themselves do not 
cause the disease, but as IAA are detected in the initial pathogenesis of human and NOD mouse 
T1D. (Pro)-insulin has been identified as a dominant autoantigen in T1D and might trigger the 
process of beta-cell autoimmunity and destruction [70,71]. IAA in NOD mice is usually 
detected after 6 weeks of age and reach a maximum between 8 and 16 weeks and then decline 
[64]. NOD mice do not necessarily express positive IAA values when diagnosed with 
symptomatic diabetes. NOD mice expressing IAA at 8 weeks of age develop diabetes earlier. 
Interestingly, eliminating immune responses to insulin blocked not only generation of T1D and 
insulitis but also immune responses to downstream autoantigens, such as the islet-specific 
glucose-6-phosphatase catalytic subunit-related protein (IGRP) in NOD mice [72]. Moreover, 
beta-cell autoimmunity in NOD mice is avoidable by tolerogenic expression of proinsulin long 
term in the APCs [73]. The host lab demonstrated that oral delivery of human proinsulin 
together with IL10 by genetically modified Lactococcus lactis (L. lactis) bacteria and a short 
induction course of anti-CD3 reversed established T1D in mice long term [74](see 1.3.3.1.1). 
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However, insulin-based trials to prevent or reverse diabetes in humans have failed to 
demonstrate a therapeutic benefit (see 1.3.1). 
ICA was first described in the 70s [75] and are detected in 70 to 80% of individuals with new-
onset T1D. ICA positivity declines after clinical diagnosis of T1D. After ten years, only 5% of 
the diabetic patients remain ICA positive. In the Diabetes Prevention Trial-1 (DPT-1), a 
multicenter study, non-affected relatives of people with T1D who were screened for ICA 
positivity and then found to have low first-phase insulin responses to intravenous glucose 
challenge had a 5-year risk of the development of T1D of 60% and a projected 10-year risk near 
90%. 
In the 90s, GAD was discovered to be the 64 kDa molecular weight islet autoantigen that was 
immunoprecipitated by diabetic (but not non-diabetic) sera [76]. GAD catalyzes the conversion 
of glutamic acid to the inhibitory neurotransmitter GABA (γ-amino butyric acid). Biochemical 
analysis has shown that GAD is found in a variety of tissues, with highest concentrations in the 
nervous system. GAD is an intracellular enzyme, and thus it is not normally expressed on the 
surface of the beta cell [77]. Although there are two major isoforms of GAD, GAD 
autoantibodies (GADA) which are more frequently detected are those directed against GAD65 
(65 kDa molecular weight) instead of GAD67 (67 kDa molecular weight). GADA are found at 
similar rates (70 to 80%) as ICA in patients with new-onset T1D. GADA testing is preferred 
over ICA testing when the diagnosis of latent autoimmune diabetes of adulthood (LADA) is 
sought in individuals with long-standing diabetes since after the onset of T1D, GADA is more 
persistent than ICA [78,79]. 
IA-2A was detected by screening an insulinoma expression library for reactivity with sera from 
T1D patients. IA-2A is less common at the onset of T1D (around 60%) than either ICA or 
GADA [80]. Unquestionably, as the number of islet autoantibodies expressed by a non-diabetic 
individual rising, their risk for T1D also rises. Individuals positive for a single islet autoantibody 
are far less likely to develop T1D than individuals who are positive for multiple islet 
autoantibodies. In general, the number of islet autoantibodies expressed by an individual is a 
more important predictor of T1D than any specific combination of islet autoantibodies [81]. In 
DPT-1 per year of follow-up, T1D developed in approximately 15% of unaffected first-degree 
relatives who were repeatedly positive for ICA and had persistent low insulin secretion in 
response to intravenous glucose [82]. The greater the number of islet autoantibodies present, 
the greater the risk of developing T1D: the risk for T1D in 4-autoantibody-positive individuals: 
50%; the risk of T1D in 3-autoantibody-positive individuals: 40%; the risk of T1D in 2-
autoantibody-positive individuals: 16%; the risk of T1D in 1-autoantibody-positive individuals: 
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3%; and the risk of T1D in 0-autoantibody-positive individuals: 0.5%. For IAA determinations, 
the CVs are considerably larger (e.g. up to 20 – 25%).  
ZnT8A were first described in 2007, and ZnT8A have the potential to be the fourth major 
biochemical autoantibody and the fifth overall major islet autoantibody[83]. In young patients 
with new-onset T1D, 63% were positive for ZnT8A (vs. 72% positive for GADA, 68% positive 
for IA-2A, and 55% positive for IAA). Following the onset of T1D, ZnT8A concentrations 
decline rapidly [84]. In young patients with new-onset T1D who were negative for ICA, GADA, 
IA-2A, and IAA, 26% were positive for ZnT8A [85]. Of new-onset T1D patients tested for 
GADA, IA-2A, and IAA, 6% were negative for all three autoantibodies. However, when 
ZnT8A testing was added to this panel, only 2% of new-onset T1D patients were islet 
autoantibody negative. Whereas 72% of new-onset T1D patients were positive for 2 or more 
autoantibodies when testing was limited to GADA, IA-2A, and IAA, the addition of ZnT8A 
testing increased the number of individuals positive for 2 or more autoantibodies to 82%. 
Whereas IAA prevalence at the onset of T1D declines with increasing age of the patient, ZnT8A 
becomes more common at onset with increasing age. This finding argues in favor of testing for 
all four biochemical autoantibodies when a marker of islet autoimmunity is sought. The 
predictive value of ZnT8A for T1D development was evaluated in 43 subjects in the Diabetes 
Autoimmunity Study of the Young (DAISY) study (30 first-degree relatives of T1D patients 
and 13 individuals from the general population; mean age at onset of T1D: 7 years). Based on 
HLA-DR and HLA-DQ genotype, or family history, DAISY consecutively follows children at 
increased risk for T1D. Comparable to other biochemical autoantibodies, ZnT8A were found 
in 63% of individuals before T1D development (vs. 70% positivity for GADA before T1D 
onset; 52% for IA-2A, and 85% for IAA). IAA were most commonly the first autoantibodies 
to be detected, followed by GADA, ZnT8A, and IA-2A. The later presence of ZnT8A suggests 
that reactivity to ZnT8 may reflect progressive beta-cell destruction. In 88 participants in the 
DAISY study who were more than three years old and were followed for more than one year, 
positivity for one biochemical autoantibody (excluding ZnT8A) yielded a 7% risk of T1D. 
However, when ZnT8A were present together with GADA, IA-2A, or IAA, the risk for T1D 
rose approximately 5-fold to 37%. As noted above, natural variants of ZnT8 exist.  
 
1.2.4 Immune cells 
During T1D progression immune cells – macrophages, B cells, natural killer (NK) cells and T 
cells (mostly CD8+ T cells) – invade the pancreatic islets generating an inflammatory condition 
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called insulitis (Figure 1.1). More than 100 years ago, this condition was first described in a 6-
year-old girl who died from ketoacidosis complications [86]. 
 
Macrophages and dendritic cells (DCs) are APCs being among the first cells to infiltrate the 
pancreatic islets during diabetes development in T1D animals [87]. Recent studies 
demonstrated that the myeloid cells found in NOD islets are typically composed of Batf3-
dependent F4/80+ macrophages with few CD103+ DCs [88]. This infiltration precedes the 
invasion of the islets by B cells, T cells, and NK cells. The activation of autoreactive T cells 
may be initiated from the processing and presentation of pancreatic islet autoantigens by APCs. 
Inactivation of macrophages in T1D animals significantly prevents T1D development [89,90]. 
Further studies showed that macrophages are required for the generation of autoreactive T cells 
that destroy beta cells in NOD mice. T cells in the macrophage-depleted 8.3-T-cell receptor 
(TCR)-beta transgenic NOD mice did not destroy transplanted NOD islets, indicating that T 
cells in a macrophage-depleted environment lose their ability to differentiate into beta-cell-
specific cytotoxic T cells [91]. While circulating monocyte-derived, tissue-infiltrating 
macrophages (Ly6C+) have a proinflammatory phenotype and function in T1D [92,93], the role 
of their tissue-resident or controlling equivalents (Ly6C−) is less known. Recently, a new class 
of immunoregulatory tissue-resident macrophages (CD39+, CD73+ and galectin-9+) has been 
identified and found to be reduced in NOD islets [94](Figure 1.1). After tissue infiltration, 
Ly6C+ monocytes can develop into either macrophages or DCs. 
DCs are essential for both the priming of naive T cells for protective immune responses and the 
purging of the T-cell pool for autoreactive clones. DCs are the most potent APCs allowing them 
to professionally take-up and cross-present processed antigen fragments to T cells. Depending 
on the differentiation state of DCs, antigen cross-presentation can lead to functional activation, 
deletion, or anergy of T cells (reviewed in [95]). Several groups have demonstrated that 
compared with those from non-autoimmune-prone mice, NOD DCs do not mature normally in 
response to a variety of stimulatory signals [96,97]. This could be of significance because a 
higher level of stimulation is required to induce T-cell deletion by activation-induced cell death 
(AICD) than needed to trigger effector T-cell function. In NOD mice, microcytic DCs 
(CD11c+CD11b−/loCD8α−PDCA-1−) which can mediate cross-presentation of islet antigens to 
CD4+ and CD8+ T cells in the draining lymph nodes are found in high numbers [98]. When 
loaded with antigen these DCs can rescue CD8+ T cells from peripheral anergy and deletion, 
and stimulate autoreactive CD4+ T cells [99]. On the other hand, pre-diabetic NOD mice have 
low numbers of tolerogenic CD8α+CD103+Langerin+ DCs, with reduced expression of CCR5, 
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CLEC9A, and IL10, locally in the pancreas [100]. Collectively, these data suggest that 
imbalances between damaging and tolerogenic cells (i.e. macrophages, DCs but also T cells) 
may surely contribute to the initiation of the disease (Figure 1.1).  
B cells have the ability to secrete antibodies and cytokines, and present antigens (Figure 1.1). 
The islet autoantibodies (for insulin, GAD65, IA-2, and ZnT8) secreted by B cells are currently 
used as diagnostic and prognostic criteria and also as surrogate markers for disease activity. 
These autoantibodies are not believed to instigate T1D but, rather, provide evidence of 
autoreactive T-cell/B-cell interactions. NOD mice in which B cells express membrane-bound 
(but not secretory) immunoglobulins (Igs) develop T1D with penetrance comparable to regular 
NOD mice [101]. Antigen-experienced B cells can present antigens and secrete cytokines which 
can either encourage or suppress immunity. Each B cell recognizes a single antigenic epitope 
on folded proteins via the antibody variable (V) region of its B-cell receptors (BCRs), 
internalizes that protein, and processes it into peptide fragments for presentation on the MHC-
II molecules to T cells. Thus, autoreactive B cells are uniquely equipped to turn-on autoreactive 
T cells. In fact, several studies have irrefutably demonstrated that B-cell-deficient NOD mice 
do not develop T1D [102] in addition to NOD mice with a B-cell-restricted deficiency of the 
MHC-II (I-Ag7 in NOD) molecule [103]. NOD mice with transgenic B cells which do not 
recognize an islet antigen (i.e. insulin) fail to develop diabetes, while skewing the B-cell 
repertoire towards insulin promotes diabetes development [101,104]. Also, peripherin-
autoreactive B cells are potent contributors to T1D pathogenesis [105]. While B cells likely 
play an important role in T1D pathogenesis via antigen cross-presentation to CD4+ and CD8+ 
T cells, these interactions seem not required for the initial recruitment of T cells to the pancreas. 
In new-onset diabetic NOD mice, long-term disease reversal was observed in mice treated with 
anti-CD20 [106]. Some initial clinical success was described with a B-cell targeting approach 
(i.e. rituximab) as T1D intervention strategy [107]. However, follow-up studies demonstrated 
that C-peptide improvement was limited to the early period after rituximab administration and 
disappeared [108]. Moreover, the appearance of new autoreactive B cells [109] and the 
depletion of IL10-producing regulatory B cells [110] after rituximab therapy question the 
usefulness of this approach as single agent therapy. 
T cells are accepted as the most important players in a pancreatic beta-cell loss in T1D, with 
CD4+ and CD8+ T cells bearing autoreactive TCRs being critical for T1D pathogenesis (Figure 
1.1). In humans, CD8+ T cells primarily invade the pancreatic islets [111], yet their activation 
and proliferation probably require CD4+ T-cell support. For example, studies performed within 
the framework of the Pancreatic Organ Donors with Diabetes (nPOD) network demonstrated 
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that islet-specific hyper-expression of HLA class I molecules is a consistent observation in post-
mortem pancreatic samples from T1D patients but not from healthy individuals and that CD8+ 
T cells dominate the lymphocytic infiltrate [111]. Not only do pancreatic islets of T1D patients 
have an increased antigen presentation capacity for CD8+ T cells, they also promote infiltration 
of the chemokine receptor CXCR3+ T cells via secretion of the interferon (IFN)-γ-inducible 
protein 10/CXCL10 [112,113]. The CXCR3 receptor can guide effector CD8+ T cells toward 
activated DCs to receive further “help” from CD4+ T cells or recruit them to inflamed tissues. 
CD4+ T cells can pick from several differentiation fates following activation, and this choice 
has profound consequences for their cytokine production and migratory potential. Initial models 
of T-cell generation concentrated on the dichotomy between T helper-1 (Th1) and Th2 immune 
reactions, with T1D being viewed mainly as a Th1-mediated pathology. However, several extra 
fate choices have appeared, including Th17 cells and follicular helper T (Tfh) cells (reviewed 
in [114]). Under an IFN-γ signal transducer and activator of transcription (STAT) 1-dependent 
signal, naïve CD4+ T cells develop into Th1 cells, through the activation of the transcription 
factor T-bet (T-box expressed in T cells). Th1 cells are important for macrophage and CD8+ T-
cell activation and clearance of intracellular pathogens. Increasing levels of IFN-γ correlated 
with diabetes progression in NOD mice [115], and IFN-γ is required for diabetes induction in 
a virus-induced T1D model [116]. In this view, Th1 has a strong relation with autoimmune 
T1D. Th2 cells are key coordinators of humoral immune responses. The key transcription factor 
in Th2 differentiation is GATA (GATA-binding protein) 3. Th2 cells stimulate IgM, IgG1, and 
IgE synthesis by B cells and activate eosinophils, thus promoting hypersensitivity responses 
due to their capacity to produce IL4, IL5, IL10, and IL13. The exogenous provision of IL4 was 
shown to inhibit diabetes in NOD mice [117], and transgenic expression of IL4 in the islets 
under the control of the insulin promoter completely prevented diabetes development [118]. 
The cornerstone of the Th1/Th2 dichotomy is that Th1 and Th2 cells negatively cross-regulate 
the function of one another through their characteristic cytokines [119]. Unlike Th1, Th2 cells 
are often described to have protective effects on beta-cell autoimmunity, although this view is 
oversimplified as Th2 cells and their mediators have been shown to facilitate the immune 
invasion of the islets [120] and accelerate beta-cell autoimmunity [121].  
With the discovery of IL17-producing (Th17) cells, the Th1/Th2 paradigm was seriously 
revised and this opened the discussion that tissue-specific autoimmunity might be driven by 
Th17 cells rather than Th1 cells. The Th17 development requires TGF-β and STAT3 activation 
in response to IL6, which in turn triggers the transcription factor retinoic acid-related orphan 
receptor (ROR)-γt. To date, the role of Th17 cells in diabetes remains indeterminate. In murine 
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studies it is suggested that IL17 is upregulated in the early stages of diabetes development 
[122,123], however, it was also shown that silencing IL17 expression did not protect NOD mice 
from diabetes [124]. Th17 cells from BDC2.5-TCR transgenic mice were capable of inducing 
diabetes but appeared to achieve this by differentiating further to a Th1 phenotype [125,126]. 
Indeed, the subsequent pathology could be inhibited by antibodies to IFN-γ but not IL17 
[125,126]. Conversely, two reports documented the ability of IFN-γ deficient Th17 cells to 
transfer diabetes successfully [127,128], arguing against the requirement for a Th1 transition. 
Fate mapping experiments in mice established that in autoimmunity, IL17-positive T cells can 
initiate IFN-γ production leading to the presence of a substantial number of T cells co-
expressing both cytokines. Interestingly, cells co-producing IFN-γ and IL17 (Th1/Th17 cells) 
have been implicated in T1D development. By measuring IFN-γ transcripts within sorted IL17-
producing cells, a study in T1D children found an increased frequency of IL17 cells to make 
IFN-γ compared with healthy controls [129]. Additionally, both IL17 and IFN-γ were up-
regulated at the mRNA level within the pancreatic islets of an individual who died within 5 
days of T1D diagnosis [123]. Besides Th1, Th2 and Th17 cells, Tfh cells have also been 
implicated in T1D pathology [130]. These cells are essential for the formation of germinal 
clusters, specialized structures in secondary lymphoid organs in which maturation of B cells 
into high-affinity plasma cells and long-lived memory B cells takes place. Both mice and 
patients with T1D seem to have an expansion of their Tfh cells. Moreover, Tfh cells might be 
the source of IL21 production in T1D [130]. IL21 is a cytokine with the capacity to act on 
different cell types, including CD4+ and CD8+ T cells, NK cells, B cells, macrophages and DCs. 
In a TCR transgenic diabetes model, a mutation in Roquin leading to aberrant Tfh development 
dramatically enhanced diabetes generation [131]. In a second TCR transgenic model, based on 
a different pancreatic antigen and different transgenic T cells, enriching for Tfh cells increased 
their capacity to cause diabetes upon adoptive transfer [130]. Although IL21 is the characteristic 
cytokine associated with Tfh cells, they are also known to be capable of producing other 
cytokines, including IFN-γ, which could explain the association of this cytokine with T1D 
[132]. Several studies have implicated repeated antigen presentation in Tfh development [133], 
a concept that fits with the inability of autoantigens to be cleared in a disease context.  
Recent literature present new insights in T1D pathogenesis demonstrating that T cells specific 
for beta-cell antigens exist normally in healthy individuals, but are prevented from their 
autoreactivity by immunoregulatory mechanisms, especially through the actions of Tregs 
(reviewed in [134,135])(Figure 1.1). T1D may develop from a failure to suppress autoreactive 
T cells by immunoregulatory mechanisms, permitting them to become activated, expanded, and 
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finally enter a cascade of inflammatory processes, leading to progressive beta-cell destruction. 
Tregs are a diverse population of lymphocytes that can counterbalance adaptive immune 
responses. Tregs counteract autoreactive T cells, induce tolerance, and reduce inflammation 
[136–142]. Among these regulatory cell populations are natural Tregs (nTregs; CD4+Foxp3+ T 
cells) that arise in the thymus during early fetal development as a consequence of positive 
selection involving interactions of “intermediate affinity” [143,144], whereas conventional 
CD4+ T cells are selected based on “low affinity” interactions. nTregs can suppress CD4+ T 
cells, CD8+ T cells, NK cells, DCs, monocytes/macrophages, B cells, basophils, eosinophils, 
and mast cells [144,145]. IL2 is essential for nTreg development, function, and homeostasis 
(i.e., CD25 is the α-chain of the high-affinity IL2R)[146]. Interestingly, CD45RA+ naïve and 
CD45RO+ memory Tregs respond to low IL2 concentrations, while other lymphoid populations 
(i.e. naïve and memory CD4+ T cells, naïve and memory CD8+ T cells and CD56hi and CD56lo 
NK cells) need much higher IL2 concentrations (3 vs. 100 pmol/l)[147]. The suppressive 
function of Treg cells is directed by the transcription factor X-linked gene forkhead box p3 
(Foxp3). Although Foxp3 expression is widely used as a marker of the Treg lineage, Treg fate 
seems to be regulated by a multifactorial signaling cascade, involving cytokines, transcription 
factors, and epigenetic modifications [148,149]. Foxp3 expression and the Treg phenotype can 
also be attained by peripheral T cells, exemplifying that Treg fate is not automatically conferred 
during thymic development. Indeed, besides the thymus-derived nTregs, there are also 
peripherally-generated adaptive or induced Tregs (iTregs) of variable phenotype and function. 
Both subsets have comparable phenotypic features and similar regulatory function against T-
cell-mediated immune responses and diseases. Both Tregs express the Treg markers IL2RA (IL-
2R α-chain; also known as CD25), FOXP3, CTLA4, TNFRSF18 (TNFR superfamily member 
18; also known as GITR) and ICOS (inducible T-cell co-stimulator), but nTregs exhibit a higher 
expression of PD-1 (programmed cell death-1), NRP1 (neuropilin-1), HELIOS, and CD73 
compared with iTregs [150]. The most important iTregs are the Tr1 cells that secrete IL10 [151–
153], the Th3 cells that secrete TGF-β and IL10 [152], and Foxp3+ iTregs). Tr1 cells are capable 
of secreting high levels of IL10 and TGF-β in the human and mouse and also secrete low levels 
of IL2, IL5, and IFN-γ [151,153]. An important growth factor for Tr1 cells is IL15, which can 
support Tr1 cell proliferation even without TCR activation [151,153]. Tr1 cells are anergic and 
proliferate poorly upon antigen-specific activation which is likely due to the autocrine 
production of IL10 leading to suppression of proliferation [151,153]. The mechanism of 
suppressive effects with Tr1 cells is soluble factor-based (i.e., IL10), and the suppressive effects 
of Tr1 cells are annulled by anti-IL10 neutralizing antibody in vitro [151,153]. Th3 cells are 
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induced from naive CD4+ T cells by TGF-β and have an important role in oral tolerance to non-
self antigens and counterbalancing autoimmune reactions [154]. Th3 cells secrete TGF-β, 
which has immunosuppressive effects acting through a soluble factor mechanism. Th3 cells 
have a reciprocal relationship with Th17 cells [155,156]. 
To date, it is clear that defects in the frequency [157] and especially in the suppressive capacity 
of Tregs from T1D patients [122,157,158] exist. 
NK cells were originally described as large granular lymphocytes with natural cytotoxicity 
against tumor cells and provide early and rapid responses to viral infections. NK cells were later 
recognized as a separate lymphocyte lineage, with both cytotoxicity and cytokine-producing 
effector functions, particularly IFN-γ. The role for NK cells in T1D is conflicting and so far, 
inconclusive. Since some studies in islets from T1D patients are not concordant, with a few 
reporting NK-cell infiltrates and altered frequencies in peripheral blood of new-onset T1D 
patients [159,160] and others reporting no presence of these cells [161]. Animal studies are also 
inconsistent, with some showing that NK-cell depletion [162] or attenuation of their function 
reduces disease [163]. A pathogenic role for NK cells has more recently been supported in a 
model of coxsackie B4-induced autoimmunity, where NK cells were important for disease 
progression [163]. Probably the presence of NK cells indicates a distinct etiology of disease, 
since there is a correlation between virus infection and T1D with virus infection being the 
initiating event [164]. 
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Figure 1.1. Immunopathogenesis of T1D. Islet-cell fragments are phagocytosed by APCs, such as macrophages 
and DCs. APCs process these islet-specific proteins to peptides that are presented by MHC class II molecules to 
proinflammatory Th1/Th17 cells, which in turn trigger several immune responses, including activation of B cells 
(producing islet autoantibodies) and islet antigen-specific (effector/memory) T cells that can directly kill beta cells 
presenting islet peptides by MHC class I molecules. Alternatively, APCs can present islet antigenic peptides to 
Tregs but these are often defective in suppressing the proinflammatory cascade, preventing beta cells from being 
destroyed (adapted from [165]). 
 
1.3 PREVENTION AND INTERVENTION 
Longitudinal studies in individuals at risk of developing T1D have clearly indicated that the 
pathology is a continuous process that progresses at anticipated steps through distinctly 
classifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of beta-
cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with 
normoglycemia and is presymptomatic, stage 2 as the presence of beta-cell autoimmunity with 
dysglycemia and is presymptomatic, and stage 3 as the onset of symptomatic disease [166]. 
Thus, prevention and intervention studies will depend on the stage of the disease (Figure 1.2). 
These cure-targeted strategies can be divided in primary prevention (before the functional loss 
of beta cells), secondary prevention (before the onset of symptomatic disease) and tertiary 
prevention and intervention (after the onset of symptomatic disease). 
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Figure 1.2. Curative strategies and interventions for T1D split up by disease stage (adapted from [11]). 
 
1.3.1 Primary prevention 
Primary prevention trials focus on young children with high genetic susceptibility for T1D. 
However, finding these kids in the general population is severely hindered by the low specificity 
of the genotypes described in the literature. On the other hand, the specificity is much higher in 
populations with a higher a priori risk of T1D, i.e., first-degree relatives. These strategies 
attempt to “cure” the core of the pathology and aim at modifying or modulating the imbalances 
in the (auto)immune system. It is known that during the early pre-diabetic state, beta cells can 
already show abnormal phenotypes with one pathognomonic mark being the increase in HLA 
class I expression in both insulin-deficient and -containing islets [111,167]. Currently, primary 
prevention trials include largely low-risk dietary modifications: elimination of cow’s milk 
(ClinicalTrials.gov Identifier: NCT01055080; ClinicalTrials.gov Identifier: NCT00570102) or 
gluten (BABYDIET-Study – ClinicalTrials.gov Identifier: NCT01115621; TEFA family 
prevention – ClinicalTrials.gov Identifier: NCT02605148 ) and supplementation of diet with 
ω-3 fatty acids (ClinicalTrials.gov Identifier: NCT00333554) or vitamin D (2,000 IU/day; 
ClinicalTrials.gov Identifier: NCT00141986; [168]). In addition, trials of antigen-specific 
immunomodulation are giving insulin (DPT-1 – ClinicalTrials.gov Identifier: NCT00004984; 
oral insulin – ClinicalTrials.gov Identifier: NCT00419562; Pre-POINT-Early Study – 
ClinicalTrials.gov Identifier: NCT02547519) as this was found previously to be safe in large 
secondary prevention trials (see 1.3.2). 
Stage 1
Prevent beta-cell autoimmunity = vaccines
Stage 2
Halt beta-cell attach = immunomodulators
Restore beta-cell loss = beta-cell regeneration
Stage3
Restore beta-cell function = beta-cell replacement/regeneration
Arrest further beta-cell loss = immunomodulators
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1.3.2 Secondary prevention 
The patients included in secondary prevention trials are those with high genetic risk and having 
positivity for two or more islet autoantibodies. The majority of young individuals with multiple 
islet autoantibody positivities progresses to diabetes in 5 to 10 years; however, the rate of 
progression decreases with age. As the pathology progresses, immune cells (i.e. mainly CD8+ 
T cells, macrophages, B cells and CD4+ T cells) start to invade the islets of Langerhans and 
selectively destroy the insulin-secreting beta cells. At this stage, one needs to target the diseased 
immune system that attacks the beta cells but also needs to restore the functional beta-cell loss. 
Some prevention trials have found no effect on the rate of progression to symptomatic T1D 
(reviewed in [169]): insulin administered parenterally (i.e. subcutaneous; [170], orally [171] or 
intranasally [172] in addition to nicotinamide administered orally [173]. Interestingly, a post 
hoc analysis of data from the DPT-1 study of oral insulin suggested that relatives with high 
levels of IAA appeared to experience a delay in the progression to disease by approximately 4 
years [171]. Even if the secondary prevention trials failed to prevent or delay the onset of 
diabetes thus far, a growing body of evidence suggests that prevention of diabetic ketoacidosis 
and hospitalization in newly-diagnosed children is possible and should be a major goal of 
diabetes care systems. In the meanwhile, new studies have been initiated (oral insulin: 
ClinicalTrials.gov Identifier: NCT00419562; nasal insulin: ClinicalTrials.gov Identifier: 
NCT00336674; and GAD-alum: ClinicalTrials.gov Identifier: NCT01122446) and the field is 
eagerly awaiting the conclusions. 
 
1.3.3 Tertiary prevention and intervention 
In tertiary prevention trials, the main aim is the preservation of remaining beta cells and the 
induction of prolonged (partial) remission. Unfortunately, autopsy studies of beta-cell mass 
reported that diabetic patients, at diagnosis, have only ~10% of their beta cells left [174,175] 
and studies in new-onset patients revealed residual beta-cell function of approximately 40% of 
normal [176] while the autoimmune beta-cell destruction further progresses. A loss of beta-cell 
mass of ~50% in animals leads already to dysregulated insulin secretion and induction of insulin 
resistance. Residual beta-cell function can be retained for decades after the onset of diabetes in 
a subset of patients. However, for most patients very little normal beta-cell function is 
maintained, beta-cell apoptosis goes on, and there is negligible spontaneous beta-cell 
regeneration [177]. Pathological pathways covering disturbances in the expansion and 
development of either endocrine or exocrine pancreas are presumably part of the early immune 
pathogenesis of T1D. Interestingly, the group of P. Herrera found that in the pancreas new beta 
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cells can be generated throughout life after near total loss, although in the absence of 
autoimmunity, mainly by the spontaneous reprogramming of glucagon-producing alpha cells 
and somatostatin-producing delta cells [178,179]. Collectively, the major goal of tertiary 
prevention trials is a prolongation of residual beta-cell function, rather than complete disease 
remission. Benefits may include simpler insulin regimen, lower glycosylated hemoglobin 
(HbA1c), and reduced risk of hypoglycemia and microvascular complications. Cure-targeted 
interventions go one step further and have as goal to restore beta-cell function and halt further 
beta-cell loss. Here, several strategies can be envisaged: antigen-specific vaccines combined or 
not with (global) immunomodulators and beta-cell replacement or regeneration. 
 
1.3.3.1 Antigen-specific vaccines 
Diverse mechanisms have been proposed to trigger suppression of autoimmunity by antigen-
specific approaches (i.e antigen- or peptide-based therapies, with or without adjuvants, through 
more exceptional strategies such as Treg therapy [180,181], tolerogenic DC vaccines [182–
184], or DNA and peptide-MHC-based vaccines [185](Figure 1.3). 
 
1.3.3.1.1 Antigen- or peptide therapy 
The tolerance induction by antigen-specific vaccines is perhaps one of the most interesting 
options at stage 3 of the autoimmune T1D process. There are several routes to induce tolerance 
(e.g. oral [186], intranasal [187], intrathymic [188,189], subcutaneous [190,191], intradermal 
[192], intramuscular [193]). However, not one of the many antigen-specific therapies that have 
been initiated during the last 30 years in T1D patients has managed to achieve clinically 
significant benefit with a therapy that has an acceptable risk profile (reviewed in [169]).  
Immunotherapies with insulin-related molecules are surely an interesting approach. However, 
although a modified peptide ligand of the immunodominant insulin B chain amino acids 9 to 
23 peptide (insulin B:9-23)(NBI-6024; from Neurocrine Biosciences Inc.) demonstrated 
immunologic efficacy in a phase I study [194] it was ineffective in phase II B trial. Nevertheless, 
up to two years after the single injection, antigen-specific Tregs could be isolated from 
peripheral blood from subjects in the experimental arm, while not in the control arm. 
The DiaPep277 peptide of heat shock protein 60 (HSP60) (from Hyperion Therapeutics Inc) 
was reported to preserve C-peptide in a small trial of LADA patients with relatively short 
follow-up [195]. However, Phase II trials in children showed no [196] or little [197] effect. 
Moreover, the company stopped developing the DiaPep277 vaccine for new-onset T1D patients 
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based on scientific misbehavior, including conspiracy with a third-party biostatistics company 
who obtained insights in the blinded data of the Phase III DIA-AID study and used these to 
manipulate the analyses to obtain satisfactory results. 
The Diamyd vaccine (from Diamyd Medical AB) is based on the whole recombinant human 
GAD65 (rhGAD65) molecule formulated with aluminum hydroxide (GAD-alum) and has 
shown some efficacy. Clinical benefit was demonstrated in studies of LADA patients [198] and 
in children with new-onset T1D [191]. These studies showed that the maximum stimulated C-
peptide decreased less in the GAD-alum group compared to the placebo group. However, more 
recent trials with GAD-alum in new-onset T1D patients were negative, despite GAD65-specific 
cellular and humoral immune responses after GAD-alum intervention [199,200]. Based on this 
knowledge, current research focusses on combinations in which the Diamyd vaccine is given 
together with anti-inflammatory and immunosuppressive agents including GABA 
(ClinicalTrials.gov Identifier: NCT02002130). Other combinations that are running in new-
onset diabetic patients are the Diamyd vaccine combined with vitamin D (ClinicalTrials.gov 
Identifier: NCT02387164 and NCT02352974) alone or with ibuprofen (ClinicalTrials.gov 
Identifier: NCT01785108) or etanercept (ClinicalTrials.gov Identifier: NCT02464033). 
While pre-clinical research is extremely important in instructing us on how T1D develops, 
making the jump from animal models of “cures” to remedies that actually work in human 
subjects has been challenging. There are multiple strategies that can prevent and a few that can 
reverse T1D in NOD mice. This has led to major criticism on the suitability of the NOD mouse. 
However, these disappointments in translation to the patient may prove useful in revealing both 
the similarities and dissimilarities between T1D in mouse and men. These observations also 
strengthen the necessity to standardize the disease stage, the assessment of immune and 
therapeutic targets, and therapeutic outcome in the NOD mouse. Timing and dosing thresholds 
for effective prevention or reversal are critical. The host lab published some studies on immune 
tolerance induction in the NOD mouse by intragastric delivery of islet antigens by genetically-
modified L. lactis. We reached approximately 60% of new-onset diabetes remission in NOD 
mice when the L. lactis-based vaccine producing human proinsulin along with IL10 was 
combined with a short course of sub-therapeutic doses of anti-CD3 mAbs [74]. When using a 
similar approach consisting of a combination of L. lactis secreting GAD65370–575 along with 
IL10 and an induction course with low doses of anti-CD3 the disease reversal rate was 67% 
[201]. We now find ourselves at a crucial point: the molecular understanding, the concept of 
oral tolerance induction, and the advantage of using recombinant L. lactis therein are present 
and could make the difference in the treatment of T1D (reviewed in [202]). 
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1.3.3.1.2 Treg therapy 
The approach to replace or correct the Treg subsets in T1D patients and thereby restoring the 
immune imbalances holds huge promise. Several researchers endeavored to induce and expand 
Tregs with different agents (reviewed in [203]), and thus provide long term tolerance of beta 
cells in T1D [181] but few of them have led to trials in T1D subjects with varying success rates. 
The host lab found that 1,25-dihydroxyvitamin D3, and its non-hypercalcemic structural analog 
TX527, promote a stable Treg phenotype in T cells from healthy controls and T1D patients 
[204]. These findings warrant further confirmation of vitamin D-induced Tregs in view of 
impending autologous adoptive immunotherapy in T1D. A Phase I trial in T1D patients 
receiving, in four dosing cohorts, ex vivo-expanded autologous CD4+CD25+CD127lo/– 
polyclonal Tregs reported no adverse effects. Immunological phenotypic studies demonstrated 
transient rises in recipient Tregs with broad CD4+CD25hiCD127loFoxp3+ phenotype longterm 
[180] (ClinicalTrials.gov Identifier: NCT01210664). These observations are encouraging and 
justify further studies (ClinicalTrials.gov Identifier: NCT02772679) but especially reinforce 
the development of Phase II trials to test the efficacy of the Treg therapy. 
 
1.3.3.1.3 Tolerogenic DCs 
Under normal conditions, APCs, more specifically DCs, with tolerance-promoting 
(tolerogenic) properties can induce (antigen-specific) tolerance and this can be strengthened by 
other suppressor and immunomodulatory cells. As such, DC-based therapy has the potential to 
safely restore immune tolerance in T1D longterm (reviewed in [205]) The host lab and others 
have demonstrated that tolerogenic DCs generated by 1,25-dihydroxyvitamin D3 with or 
without dexamethasone have a stable maturation-resistant phenotype with low expression of 
activating co-stimulatory molecules, skewed production of IL12 and high expression of 
inhibitory molecules and IL10. These immunomodulatory cells can increase apoptosis of Teff 
cells and induce antigen-specific Tregs, which work through linked suppression ensuring 
infectious tolerance [206–209]. Moreover, the host lab found that 1,25-dihydroxyvitamin D3 
induced human monocyte-derived tolerogenic DCs by metabolic reprogramming. Both glucose 
availability and glycolysis, under the control of the PI3K/Akt/mTOR pathway, determined the 
induction and maintenance of the tolerogenic DC phenotype and functionality [210]. Presently, 
several clinical trials are testing the safety of ex vivo-generated DC vaccines (ClinicalTrials.gov 
Identifier: NCT00445913 and NCT02354911). 
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1.3.3.2 Global immunomodulators 
Several non-antigen-specific immunomodulators have been tried in new-onset T1D patients. 
Treatments with cyclosporine, azathioprine, and anti-thymocyte globulin (ATG) plus 
prednisolone had undesirable side effects, including the weakening of immunity to fight 
infections, toxicity (renal and pancreatic), and potential long-term risk of malignancies. The use 
of cyclosporine could prevent diabetes in the diabetes-prone BioBreeding rat and a pilot study 
in 41 newly diagnosed T1D patients showed its therapeutic potential in humans [211]. Of 30 
patients treated within 6 weeks of diagnosis, 16 became insulin independent with concentrations 
of plasma C-peptide in the normal range and decreasing titers of ICAs. However, these 
beneficial effects were only stable for 1 year and the patients progressed to insulin dependency 
within 3 years. Renal and beta-cell toxicity, as well as the costs of the drug and the monitoring 
of its levels in the blood, led to a consensus that the risks outweighed the benefits. Although the 
short-term renal side effects of cyclosporine were completely reversible, long-term 
cyclosporine treatment may induce irreversible structural renal damage. 
 
1.3.3.2.1 ATG 
ATG has been used in organ transplantation to avoid acute rejection but has not yet 
demonstrated effectiveness in inducing immune tolerance. This polyclonal IgG directed against 
thymocytes targets several T-cell antigens and thus creates a unique therapy directed against T 
cells that could promote tolerogenic responses in autoimmunity. In new-onset diabetic NOD 
mice, a short course of rabbit anti-mouse ATG (mATG) induced durable remission [212]. 
Studies in the 80s and 90s suggested that short courses of prednisone and ATG plus prednisone 
in new-onset T1D patients were effective in reducing insulin requirements and lowering HbA1c 
levels [213,214]. A small Phase II, randomised, placebo-controlled, clinical trial (Study of 
Thymoglobulin to Arrest Type 1 Diabetes (START); ClinicalTrials.gov Identifier: 
NCT00515099) with a brief course of ATG (6.5 mg/kg polyclonal rabbit ATG (rATG) or 
placebo over a course of four days) did not result in proper preservation of beta-cell function 
12 months after therapy stop in new-onset T1D patients [215]. Moreover, cytokine release 
syndrome and serum sickness were observed and generalized T-cell depletion with the absence 
of specific effector memory T-cell elimination could be noted. In a follow-up study 24 months 
after therapy stop, it was described that although ATG did not preserve beta-cell functionality, 
older patients had preserved C-peptide, which might warrant further study [216]. Perhaps low 
doses to avoid side effects could be of interest in combination regimens. Previously, low-dose 
ATG and granulocyte colony stimulating factor (GCSF) treatment led to a durable reversal of 
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diabetes in NOD mice. Therefore, the ATG-GCSF in New Onset Type 1 Diabetes (ATG-GCSF) 
trial will study whether low-dose ATG plus pegylated GCSF and low-dose ATG alone will 
have the ability to retain/enhance C-peptide production in new-onset T1D patients 
demonstrating residual beta cell function (ClinicalTrials.gov Identifier: NCT02215200). 
 
1.3.3.2.2 Monoclonal CD3 antibody 
The use of monoclonal CD3 antibody (anti-CD3 mAb) has been extensively studied in the 
context of avoiding acute graft rejection and autoimmune diseases. Kung et al. reported in 1979 
the development of OKT3 (Ortho Kung T3), the first murine mAb recognizing CD3 surface 
antigen on human T cells [217]. However, the use of OKT3 in humans had several undesirable 
effects. OKT3 is a potent mitogen, promoting T-cell proliferation and cytokine secretion, 
triggering a wide spectrum of adverse effects including fever, chills, nausea, vomiting and 
headaches, summarized as ‘flu-like,’ ‘cytokine-release’ or ‘first-dose’ syndrome. Because of 
these unwanted toxic effects of OKT3, two humanized non-mitogenic anti-CD3 mAb variants 
were produced. hOKT3 γ1(Ala-Ala)(teplizumab; from MacroGenics and Eli Lilly) is a 
humanized version of the mouse OKT3 mAb which preserves the OKT3 binding but has 
mutations in the Fc region: amino acids 234 and 235 were both changed to alanines, and as such 
FcR binding decreased [218]. For the aglycosylated ChAglyCD3 (otelixizumab; from TolerX 
and GSK) amino acid 297 was replaced with an alanine resulting in the elimination of a 
glycosylation site necessary for FcR binding [219]. The use of anti-CD3 over the last 20 years 
in T1D intervention has been reviewed in [220]. In the 90s, the group of L. Chatenoud 
demonstrated in new-onset diabetic NOD mice that administration of a low-dose regimen of 
hamster anti-mouse CD3 mAb 145-2C11 (5 µg/day for 5 days) induced rapid, long-lasting and 
antigen-specific remission from disease but also prevented immune responses towards 
syngeneic pancreatic islet grafts and not against unrelated antigens as shown by normal 
rejection of skin allografts [221]. Such observations, that anti-CD3 mAbs were able to break 
active beta-cell autoimmunity, but were less efficient in preventing disease, led to an important 
discovery in the field of autoimmunity and transplantation. Although administration at the time 
of transplantation induced immunosuppression, a slightly delayed treatment induced long-
lasting remission in pancreatic islet allografts [222] and heart transplantation [223], probably 
due to preferential depletion of effector memory T cells, the resistance of Tregs to anti-CD3 
mAb-induced apoptosis and establishment of local immune privilege [224]. These observations 
initiated further successful studies on anti-CD3 mAb for tolerance induction in autoimmune 
diseases. Two randomized, placebo-controlled phase I/II trials with either teplizumab or 
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otelixizumab demonstrated a slower decline in stimulated C-peptide, lower HbA1c levels, and 
lower insulin requirements in new-onset T1D patients [225–227]. The C-peptide levels held for 
at least 1 year, especially in patients with higher baseline C-peptide levels, followed by a 
recurrence of progressive loss of C-peptide. Significant but smaller benefits in C-peptide levels 
persist up to 4 years after treatment with a single course of the mAb [228]. In the meanwhile, 
both mAbs have been tested in Phase III trials in new-onset T1D patients and each failed their 
primary endpoints [229,230]. However, post hoc analyses of the ABATE trial could 
demonstrate positive effects especially in subjects enrolled in the United States, younger than 
18 years, enrolled within 6 weeks of diagnosis, and with higher levels of C-peptide at study 
entry [231,232]. To achieve better effects, this therapy will likely require repeated 
administration of the drug, which is being tested in several trials (ClinicalTrials.gov Identifier: 
NCT00378508; ClinicalTrials.gov Identifier: NCT02000817) or in combination with another 
therapeutic agent [233].  
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Several other immunomodulators have also been or are being tested in animal models of T1D 
as well as in new-onset patients and are targeting specific immune pathways (i.e. rituximab (B-
cells), abatacept (costimulation), anakinra (IL1R), vitamin D (Tregs and tolerogenic 
DCs))(Figure 1.3). 
 
Figure 1.3. Therapeutic approaches in T1D. These strategies will prime or enhance 'natural' immune regulation 
by lymphocytes, in addition to medicinal immune suppression and depletion. Each contributor in the dialogue 
between beta cells and the immune system might be more or less specifically targeted by the immune intervention. 
Many of these approaches have been or are evaluated clinically (adapted from [234]). 
 
1.3.3.3 Beta-cell replacement 
1.3.3.3.1 Pancreas transplantation 
Beta-cell regeneration or replacement are alternative therapeutic approaches for a better blood 
glucose control and improved outcomes in terms of secondary complication rates in T1D 
patients. Among beta-cell replacement options both full pancreas transplantation and islets 
transplantation are clinically available. Over the last 50 years, whole pancreas transplantation 
has evolved from a pure experimental procedure to standard therapy for patients with brittle 
diabetes and established end-stage kidney failure or with overt diabetes complications and poor 
quality of life. On the other hand, whole pancreas transplantation remains an invasive surgical 
procedure and although improvements in surgical techniques, and better characterization of 
donor and recipient have tremendously increased the success rate of vascularized pancreas 
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transplantation (i.e. the estimated half-life of a pancreas transplant is now 14 years 
(simultaneous pancreas and kidney transplant; SPK), 7 years (pancreas after kidney transplant; 
PAK) and 7 years (pancreas transplant alone; PTA)), the number of pancreas transplants, 
especially in United States, has decreased by over 20% over the past decade, most particularly 
records of solitary pancreas transplantation (i.e. PTA or PAK) procedures [235,236]. Poor 
exploitation of deceased donor pancreases might be a leading cause of the declining graft 
volumes. Moreover, not only is there a decline in a number of patients allocated to the waiting 
lists, also the numbers of deceased donors, trained surgeons, centers that actively perform 
pancreas transplantation, and referrals from endocrinologists have decreased. On top of the 
surgery, life-long immunosuppression is needed, which in turn leads to morbidity and carries a 
non-negligible risk of mortality. But the most difficult barrier to widespread use of whole organ 
transplantation as a cure for people with T1D is the scarcity of donor organs. 
 
1.3.3.3.2 Islet cell transplantation 
In a pathology where the primary cell that is destroyed is the beta-cell, isolated islet cell 
transplantation should be sufficient to cure the disease, and this procedure does not require 
surgery, but can be performed on an ambulatory basis, via intraportal injections of islets, 
lodging them in the liver [237,238]. Additionally, the fact that islets can be cultured for at least 
several weeks offers a unique opportunity to immunologically modulate the graft, and optimize 
the host conditioning prior to transplantation. Islet cell transplantation is a rapidly evolving 
technology and impressive progress has been made since 2000 when a research team from the 
University of Alberta in Edmonton developed an innovative islet transplant protocol which was 
able to achieve insulin independence and near normal HbA1c levels in 80% of T1D patients 
[239]. Interestingly, after more than 10 years from the time of the first islet cell transplantation, 
all subjects had continued islet function [240]. In the meanwhile, islet cell transplantation is 
seen as the most effective strategy to treat T1D complicated by severe hypoglycemia [9]. 
However, some difficulties remain, such as the limited supply of donor pancreatic cells, the 
necessity of several donors for a single islet cell transplantation, and graft failure due to 
metabolic pressure, continued autoimmunity, allograft rejection, systemic immunosuppression, 
and oxidative stress caused by hypoxia or inflammatory cytokines. Especially, the permanent 
immunosuppressive drug treatment and the shortage of good-quality islets have led the islet cell 
transplantation benefits to less than 0.5% of patients with T1D [241]. There may be several 
ways to overcome some of these problems by e.g. encapsulating islets isolated from other 
sources such as pigs, by reprogramming exocrine pancreatic cells to beta cells or by deriving 
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beta cells from embryonic, fetal, or other stem-cell sources [242]. In addition, cell therapy, 
especially stem-cell therapy, has recently received a lot of attention to support islet cell 
transplantation. Several types of stem cells are given special interest for their capacity to self-
renew, to differentiate into multiple lineages and for their paracrine (trophic) and 
immunomodulatory effects, making them interesting candidates in improving islet cell 
transplantation success. 
 
1.3.3.3.3 Multiple hurdles 
1.3.3.3.3.1 Limited supply of donor organs 
As in other organ transplant programs that rely on organs from deceased donors, organ scarcity 
is an issue. Moreover, Eurotransplant (https://www.eurotransplant.org/cms/) reports that only 
20-25% of the offered organs are being used for transplantation procedures. Acceptance and 
utilization might be increased by improving the quality of organ procurement, increasing the 
capacity of trained transplantation teams, and accepting organs of lesser quality (i.e. donors 
with advanced or very young age, obesity or with vascular and congenital abnormalities etc.) 
taking into account the risk of increasing post-transplant complications, cost, and number of 
organs per islet transplant. Indeed, the latter probably decreased rather than increased 
therapeutic success of islet cell transplantation [243–246].  
To liberate the islets from the whole pancreas, this organ needs to be partially enzymatically 
digested, followed by density centrifugation separation of the exocrine tissue and stroma from 
the islets [247]. Despite improvements in the islet isolation and purification techniques which 
remain demanding, labor intensive, expensive procedures and are best carried out in expert 
centers, human islet cell transplantations from a single donor have not been very successful 
worldwide [248]. Moreover, less than half of the organs donated for pancreatic islet isolation 
have yielded a suitable preparation meeting the stringent criteria for human islet cell 
transplantation. The enzymatic digestion process disrupts the islet-to-exocrine tissue adhesive 
contact. Suboptimal collagenase composition leads to incomplete digestion of islets from 
exocrine tissue along with reduced yield, decreased purity, and increased duration of 
collagenase exposure adversely affects within-islet cell-to-cell adhesion, leading to loss of islet 
integrity and viability involving mainly the beta cells [249–252]. Several studies have shown 
that immediately after isolation, the peri-insular basement membrane is absent, giving rise to 
pyknotic nuclei and apoptotic bodies, accompanied by elevated pro-apoptotic p38 and c-Jun N-
terminal kinase (JNK) activity relative to pro-survival extracellular signal-regulated kinase 
(ERK1/2) activity before transplantation has even occurred [253–255]. 
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Because the supply of human donor pancreases is extremely limited, even the most successful 
method of the human pancreas or islet cell transplantation could only cure a very small fraction 
(< 1%) of all T1D patients. So other sources of cells are needed if we want to cure all T1D 
patients. 
 
1.3.3.3.3.2 The necessity of several donors for a single islet cell transplantation 
Since the Edmonton protocol was established in 2000 its success was attributed, in part, to the 
engraftment of an enormous islet cell volume (>11,000 islet equivalents per kilo body weight 
(IEQ))[239]. In this sense, the majority of islet graft recipients need islets from over 2 donors 
to become insulin independent, which reduces the amount of patients that can be treated [256]. 
Indeed, the ability to achieve routine single donor islet infusion will ensure availability of more 
islets for an ever-expanding T1D patient group with poor glycemic control worldwide and 
would allow islet cell transplantation to match the success of whole pancreas transplantation. 
In the meantime, several studies have identified donor- and recipient-related factors associated 
with single donor transplant success such as recipient age (age ≤40 years), insulin requirement 
at entry (<0.5 U/kg/day), donor weight (>90 kg), donor body mass index (BMI >30), islet graft 
mass (>5,646 IEQ/kg), and pre-transplant heparin and insulin administration [244,245,257]. 
Currently, the intrahepatic portal vein is the only site that has been routinely performed in the 
clinical setting and results in insulin independence. On the other hand, the rapid graft failure 
and the complexity in monitoring the viability and function of the islet transplant have started 
a search for alternative implantation sites that might offer better engraftment and long-term 
survival, together with diminished procedure-related problems. The pancreas [258], spleen 
[259], anterior eye chamber [260,261], testis [262], thymus [188], bone marrow [263], muscle 
[264], peritoneum, and omental pouch [265] have been explored but few of these sites have 
found their way into the clinic 
 
1.3.3.3.3.3 Immediate graft failure 
An observation common in islet cell transplantation is the early loss of functional beta-cell mass 
of around 60% in the first hours/days after transplantation [266,267]. Several causes have been 
quoted as underlying etiologies of this rapid cell loss [268]. Half of this loss happens within the 
first 72 hours after engraftment, before adequate vascular supply is reestablished. Part of the 
non-immune graft failure is most probably due to the implantation of a suboptimal islet quantity 
and quality. Additionally, islet implantation into T1D patients exposes the insulin-producing 
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beta cells to a number of harmful factors. These include hypoxia, instant blood-mediated 
inflammatory reaction (IBMIR), non-specific inflammation, chronic hyperglycemia, and 
eventually also immune-mediated damage. 
Intrahepatic transplantation is a minimal-invasive portal vein infusion [269] that can result in 
islet entrapment in the portal branches surrounding the sinusoids [252,270]. Although this 
vascular microenvironment provides abundant physical and nutritional support to the injected 
islets which have been stripped from their dense vasculature and specialized extracellular 
matrix during the islet isolation procedure, the hepatic portal vasculature is also a hostile 
environment that limits islet engraftment and function. For example, oxygen tension in the liver 
parenchyma is well below that of the pancreas, which may lead to lower oxygen and nutrient 
supply to the inner core of islets, ultimately resulting in hypoxia and cell death [252,271]. The 
hypothesis that hypoxia, due to loss of the normal islet microvasculature, results in loss of beta-
cell mass is further supported by the increased rates of apoptosis in dispersed islets at oxygen 
tensions <10 mmHg and by the described improvement in graft oxygenation with paralleled 
reduced apoptosis rates during the first weeks after transplantation (revascularization period) 
[272]. Another major cause of immediate graft failure is the non-specific inflammatory and 
thrombotic reaction termed IBMIR, which negatively influences islet engraftment through the 
expression of tissue factor, resulting in platelet adherence, activation, clot formation, and 
lymphocyte recruitment [252,273]. The direct effect of IBMIR on immediate loss of islet mass 
and function had yet to be fully characterized but given that platelet activation is one of the 
principal contributing elements in the initiation of an inflammatory response, IBMIR is most 
likely also one of the key processes that elicits an early immune-mediated response. Following 
islet cell transplantation, especially the proinflammatory cytokines (i.e. IL-1β, IFN-γ and TNF-
α) are strongly amplified in and around the graft. Moreover, tissue-resident macrophages can 
facilitate damage to the newly infused islet cells [274]. Chemokines secreted by tissue-resident 
macrophages, ductal cells, and inflamed or destroyed endocrine cells may further attract 
recipients’ macrophages to the transplantation site [275–277] Thus, the proinflammatory milieu 
in islet grafts probably promotes loss of beta-cell viability and function. 
Implanted beta cells are placed under additional risk of damage and dysfunction by chronic 
metabolic stress [278] that can be intensified via continuous exposure to high levels of immune 
suppressive drugs [279], which are necessary to avoid immune-mediated graft rejection 
[258,278].  
 
  Chapter 1: Introduction 
 
29 
 
1.3.3.3.3.4 Alloimmunity 
The ability of recipient T cells to recognize donor-derived antigens, so-called allorecognition, 
initiates allograft rejection. Once recipient T cells become activated, which is controlled by 
both signal 1 and 2, they undergo clonal expansion, differentiate into effector T cells, and 
migrate into the graft where they provoke tissue destruction. By their particular character, 
effector memory T cells are the most potent mediators of allograft rejection (reviewed in [280]). 
Their low threshold requirement for activation and their high expression levels of adhesion 
molecules allow rapid access to the grafted tissue [281]. Moreover, clinical data demonstrated 
that enlarged frequencies of donor-specific, cytokine-producing memory T cells correlate with 
high occurrences of graft rejection and poor long-term allograft survival [282]. Moreover, T 
cells can help B cells to produce alloantibodies. Yet, the exact mechanisms of islet allograft 
rejection and the distinction between effector and memory T-cell phenotypes in the context of 
islet allograft rejection remain incompletely understood. The full understanding of these 
immunological pathways and their unique properties will be an important tool to direct the use 
of immunomodulatory drugs and optimize the application of currently available therapies. Even 
with new and better drugs coming to the market there are still undesirable side effects. Besides 
beta-cell toxicity by the immunosuppressive drugs, also predisposition of patients to secondary 
infectious diseases needs to be avoided. 
 
1.3.3.3.3.5 Autoimmunity recurrence 
Autoimmunity recurrence, besides alloimmunity, is one of the major concerns in islet cell 
transplantation in T1D subjects. The development but also the continuity of autoreactive T cells 
with an antigen-experienced memory phenotype characterize the pathological basis for 
autoimmunity recurrence after islet transplantation. These autoreactive T cells can be 
reactivated upon antigen recall through grafting of new islet/beta cells. In the past, their 
expansion was seen as a consequence of immune system hyperstimulation in an inflammatory 
environment. However, more recent data put forward that homeostatic proliferation 
(alternatively called homeostatic expansion or lymphopenia-induced proliferation), mediated 
by IL7 and IL15 [283], can be the driving force of autoreactive T-cell expansion in islet 
transplantation, especially following lymphocyte depletion strategies (i.e. rATG and the anti-
CD52 Ab alemtuzumab (Campath-1H))[284,285]. Recent publications suggest that IL7 is 
involved in the development of T cells with a stem cell-like memory phenotype [286] and in 
the bioenergetic phenotype of T cells via transcription of the glycolytic enzyme hexokinase 2 
[287]. Strategies that target IL7-mediated homeostatic proliferation of memory autoreactive T 
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cells in T1D patients after islet cell transplantation might have great promise. While rapamycin 
and FK506 have been shown to be ineffective on this pathway, mycophenolate mofetil (MMF) 
has the ability to significantly diminish the degree of homeostatic T-cell proliferation at 
therapeutic serum concentrations. IL15 seems mainly responsible for driving a basal 
proliferation of memory CD8+ T cells [288]. Poor islet transplant outcome during the first year 
after grafting was associated with the presence of peritransplant autoreactive T cells [289–291] 
and peritransplant or de novo donor-specific cytotoxic and CD4+ T cells [291,292]. In detail, 
Huurman et al. described that seven out of eight patients without pre-existent T-cell 
autoreactivity became insulin independent, versus none of the four patients reactive to both 
peritransplant islet autoantigens (i.e. GAD and IA-2)[290]. Demeester et al. reported that 
recipient HLA-A*24 status and rising autoantibody levels, mostly GADA, within 6 months 
after the first islet transplant associated with poor graft outcome [293]. Of interest, Piemonti et 
al. revealed that donor-specific alloantibodies or autoantibodies increase after islet 
transplantation and might serve as prognostic markers [294]. In this regard, van der Torren et 
al. identified serum cytokine signatures that can predict or associate with clinical outcome of 
islet cell transplantation [295]. Together, these results clearly indicate that control of beta-cell 
autoimmunity or re-establishment of self-tolerance is crucial for long-term clinical outcomes 
after islet transplantation. While the significance of the homeostatic T-cell proliferation 
pathway is increasing in T1D and islet cell transplantation, there are few drugs targeting this 
pathway in men and limited clinical studies to assess whether this could be a real approach to 
control T-cell-mediated beta-cell autoimmunity.  
 
1.3.3.4 Stem-cell therapy to advance islet cell transplantation 
Many types of stem cells exist and their potential to be used as an infinite and renewable source 
of insulin-producing beta cells to solve the problem of limited donors in human islets 
transplantation has led to stimulating avenues of application. Stem cells have the ability to self-
renew and possess multi-lineage differentiation. Both embryonic or pluripotent (which are 
derived from pre‐implantation embryos and proven to generate cells of all tissues of the adult 
organism) and adult or multipotent stem cells (which can be found in a variety of tissues in the 
fetus and after birth)(http://stemcells.nih.gov/) demonstrated encouraging outcomes in 
producing insulin in vitro and correcting high blood glucose concentrations in pre-clinical 
models. 
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However, stem cells could also contribute to better outcomes in islet cell transplantation as 
‘companion cells’ secreting trophic factors enhancing islet engraftment (revascularization), 
function and survival after transplantation (Figure 1.4). 
 
 
Figure 1.4. Modes of stem cell-based therapies in islet cell transplantation. In principle, new beta cells can be 
formed from adult stem cells residing in the pancreatic ducts or islets, through transdifferentiation of other 
pancreatic cells or via differentiation from pluripotent (ESC and iPSC) or multipotent (MSC and MAPC) stem 
cells under stringent in vitro culture conditions that try to recapitulate the embryological development of beta cells. 
Although strong insulin production in response to glucose has only been observed in hESC-derived insulin-positive 
cells, reprogramming of fibroblasts and umbilical cord cells into iPSCs have recently been successful in generating 
glucose-responsive insulin-producing cells. On the other hand, the formation of pancreatic progenitors from bone 
marrow-derived MSCs and MAPCs remains to be confirmed; however, these cells surely promote survival and 
regeneration of beta cells. Moreover, these cells can enhance islet engraftment and function by secreting trophic 
factors that can avoid apoptosis, modulate the innate and adaptive immune system, and promote revascularization. 
It is likely that MSC and MAPC effects on the immune system may be affected not only by cell-to-cell interactions, 
but also by environmental cues shaping their phenotype and functions.  
 
1.3.3.4.1 Embryonic stem cells 
Several protocols have been described to differentiate human embryonic stem cells (ESCs) into 
pancreatic progenitors [296–302]. Advancements in the understanding of embryonic beta-cell 
development have resulted in efficient directed differentiation protocols for converting 
pluripotent stem cells into pancreatic progenitors in vitro [301]. While initial studies were able 
to generate definitive endoderm from pluripotent stem cells by the introduction of the TGF-β 
family member, activin A [303], more recent studies combined retinoic acid, the sonic 
hedgehog (Shh) inhibitor cyclopamine, and fibroblast growth factor 10 (FGF10) to generate 
  Chapter 1: Introduction 
 
32 
 
pancreatic epithelium in vitro from definitive endoderm derived from pluripotent stem cells 
[299]. Meanwhile, several methods for the generation of human ESC-derived pancreatic 
epithelium are established. 
When transplanted, the pancreatic precursors derived from human ESCs had the potential to 
further differentiate into glucose-sensitive insulin-producing cells and were able to reverse 
diabetes in vivo [304–308]. In fact, chemically-induced diabetic immunocompromised mice 
transplanted with the pancreatic progenitors derived from human ESCs sustained 
normoglycemia and had comparable human insulin and C-peptide concentrations to mice 
engrafted with substantial human beta-cell mass. Removal of the grafts in these mice induced 
recurrence of hyperglycemia [307,309]. These findings suggest an important in vivo 
contribution of the graft microenvironment to the terminal differentiation/maturation of 
pancreatic progenitors into true insulin-producing cells [298,309]. Despite impressive progress, 
knowledge on the in vivo factors or circumstances required for the final maturation steps is 
limited. Moreover, the amount and characteristics of the cells within the pancreatic precursor 
population that can further differentiate in vivo have not been distinguished. Several studies in 
this field are ongoing to attempt to fully understand these processes.  
Recently, the group of T.J. Kieffer reported on a new seven-stage in vitro differentiation 
procedure that built upon protocols previously used to specify pancreatic progenitors. They 
used GDF8 (a TGF-β family member), a GSK3b inhibitor followed by FGF7, vitamin C, TPB 
(PKC activator), SANT-1 (a hh antagonist) and LDN (a small-molecule inhibitor of the BMP 
receptor) and molecules such as ALK5iII (TGF-β receptor), thyroid hormone (T3), N-acetyl 
cysteine, AXL inhibitor to generate cells that could secrete insulin after glucose stimulation in 
similar fashion as human islets in vitro and express markers of mature pancreatic beta cells such 
as MafA. Almost at the same time, the group led by D. Melton reported their own differentiation 
procedure with slight modifications, employing keratinocyte growth factor (KGF), SANT-1 
and low concentration of retinoic acid, followed by molecules that affected numerous signaling 
pathways, comprising of wnt, activin, hh, epidermal growth factor (EGF), TGF-β, thyroid 
hormone, and retinoic acid, as well as γ-secretase inhibition, to generate glucose-responsive 
beta cells from human pluripotent stem cells in vitro. In contrast to previous protocols, these 
stem-cell-derived beta cells expressed mature beta-cell markers, fluxed Ca2+ in response to 
glucose, packaged insulin into secretory granules, and produced insulin as effectively as adult 
human beta cells in response to various nutritional challenges. Xenogeneic transplantation 
experiments demonstrated that the cells were capable of rescuing chemically-induced diabetes 
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in mice [310]. Clearly, various multi-step protocols have been described in different stages of 
pancreas development with different results but also many concerns [301]. 
One concern is the low yield and purity of the pancreatic progenitors in these in vitro cultures. 
However, new methods of expansion and banking and a suspension-based differentiation 
system may generate higher yields of cells expressing markers of pancreatic endoderm [297]. 
Additionally, the probability of forming teratomas developing from contaminating pluripotent 
stem cells may impede the widespread clinical utility of human ESC-derived islet progenitor 
cells, especially in patients that may be immunocompromised through the lifelong use of 
immunosuppressive drugs. As endogenous islets, these pancreatic progenitors will also be 
vulnerable to immediate graft failure and immune-mediated destruction. Thus, a robust and 
retrievable capsule may be used to safely administer the stem-cell product by limiting the cells 
to one place but also providing some immune protection. At the moment, creating this type of 
encapsulation system is being explored by several biotech companies such as TheraCyte Inc., 
Beta-O2 Technologies Ltd., and ViaCyte Inc. The latter used pancreatic progenitors derived 
from human ESC line (CyT49 line) in a two-dimensional planar drug delivery system 
(Encaptra™) which allowed the exchange of molecules but kept the cells contained and 
protected by the recipients’ immune system [311]. Interestingly, the human ESC-derived 
pancreatic endoderm in the encapsulation system further matured to glucose-responsive insulin-
producing cells and other endocrine cells without evidence of increased biomass or cell 
escape[300]. Further analyses of the composition and function of these subcutaneously 
implanted macro-encapsulated human ESC-derived grafts revealed higher glucose-responsive 
C-peptide levels and a lower proinsulin / C-peptide ratio in animals using the Encaptra™ device 
than human islet-cell implants under the kidney capsule of immunocompromised mice [312]. 
These interesting results with macro-encapsulation of human ESC-derived pancreatic 
endoderm steered the biotech ViaCyte, Inc.to start recruiting participants for a Phase I/II trial 
called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01™ Combination Product in 
T1D patients (ClinicalTrials.gov Identifier: NCT02239354). 
 
1.3.3.4.2 Induced pluripotent stem cells 
Somatic cell reprogramming into pluripotent ESC-like cells, called induced pluripotent stem 
cells (iPSCs), is possible via the introduction of transcription factors, like Oct4, Klf4, Sox2, c-
Myc, and Lin28, under ESC culture conditions [313]. These cells can be derived theoretically 
from any adult cell, being obtained from different origin, such as fibroblasts, stomach cells, 
liver cells, keratinocytes, amniotic cells, blood cells and adipose cells [314–316]. iPSCs can 
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have the same haplotype as the recipient, allowing powerful patient-specific autologous 
therapies. Consequently, immunosuppressive drug consumption to circumvent allorejection 
may not be necessary, albeit autoimmunity will still pose a challenge. These cells would also 
avoid ethical concerns of human ESC-derived products [317]. iPSCs could ideally be directed 
down a pancreatic endocrine developmental program and then be used to generate insulin-
producing cells. This new approach has not yet progressed as far as the human ESC field, but 
several studies using directed differentiation protocols have demonstrated the production of 
pancreatic progenitors that express insulin and some other markers of mature beta cells 
[242,301,310,318,319]. 
 
1.3.3.4.3 Adult stem cells in the pancreas 
For many years, the nature and even existence of adult pancreatic stem or progenitor cells have 
been a matter of debate in the area of beta-cell replacement for diabetes, while there was no 
doubt that the fetal pancreas is rich in endocrine progenitors [320,321]. Nowadays, it is 
established that multipotent stem cells do exist in the adult pancreas [322], residing in the 
epithelium of pancreatic ducts [323] and inside the islet clusters [324]. Interestingly, beta-cell 
precursors can be activated in injured adult mouse pancreas to increase functional beta-cell 
mass by proliferation and differentiation rather than by self-duplication of endogenous beta 
cells and are located in the ductal lining [325]. Next, it was further established that stem-cell 
populations in the adult mouse pancreas can be expanded in vivo in response to beta-cell or 
pancreas injury and can be induced to proliferate and differentiate in vitro to glucose-responsive 
insulin-producing endocrine cells [326]. Collectively, these studies revealed that the adult 
pancreas maintains its capacity to reactivate its embryonic model of beta-cell development. 
Recent studies demonstrated how stem cells meet these requirements by switching between 
functional states tuned to homeostasis or regeneration [327]. This plasticity extends to 
differentiating cells, which are able of reverting to stem cells after tissue damage. 
 
1.3.3.4.4 Adult stem cells outside the pancreas 
1.3.3.4.4.1 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are the most studied adult stem cells. These cells can be 
isolated from the stromal fraction of numerous adult tissues in multiple species [328]. The MSC 
is a non-hematopoietic multipotent self-renewing stem cell that is described to differentiate 
under standardized in vitro conditions into several cell types of mesenchymal origin, such as 
osteoblasts, adipocytes and chondrocytes [329], but they also have the capacity to differentiate 
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into cell types of endo- and ectodermal lineages, including endothelial cells [330], lung 
epithelial cells [331], renal tubular cells [332] neural cells [333], hepatocytes [329], and insulin-
producing cells [334–337]. Nevertheless, such multiple differentiation competencies of MSCs 
are not universally recognized. Indeed, although MSCs can be expanded and differentiated into 
a wide diversity of cells in vitro, it remains controversial whether these cells differentiate to 
form functional tissues in vivo [338]. Hence, several studies relate the benefits of MSCs to their 
reparative effects via migration to sites of injury/ischemia and/or to their release of trophic 
factors that can influence cell migration, proliferation, and survival of surrounding cells. 
Besides, MSCs also possess potent immunoregulatory effects with the ability to modulate both 
innate and adaptive immune responses [339]. Still, as MSCs lack definitive homing 
mechanisms, these cells upon intravenous infusion often do not traffic to the damaged tissue to 
induce tissue regeneration, to treat inflammation, or to promote neoangiogenesis and instead 
get stuck mainly in the lungs [340]. 
The direct delivery of these multipotent stem cells at the site of injury will be crucial to fully 
benefit from their therapeutic effects [341]. At the site of injury, the major benefits of MSCs 
seem to be attributed to their capacity to enhance repair processes via the secretion of a variety 
of cytokines and growth factors with paracrine and autocrine activities. These secreted bioactive 
molecules can enhance neo-angiogenesis, inhibit fibrosis and apoptosis, suppress inflammation 
and even modulate the adaptive immune system by the induction of regulatory T cells and the 
recruitment of myeloid-derived suppressor cells, and stimulate differentiation of tissue-intrinsic 
(stem) cells. In the islet cell transplantation field, pre-culturing islets with MSCs using a direct 
contact co-culture system enhanced transplantation outcome in diabetic mice by improving islet 
quality, survival and function [342,343]. Here, possible explanations for the superior graft 
function of the cultured islets in vivo could be the anti-apoptotic and pro-angiogenic abilities of 
the MSCs. First, recent work identified ANXA1, also known as lipocortin-1, as a crucial MSC-
secreted factor able to enhance insulin secretion in vitro [344]. Second, improved 
vascularization of islet transplant could only be detected when MSCs were physically present 
at the implantation site [345,346]. Several studies have shown that direct contact by co-
transplanting islets with MSCs also better maintained islet cytoarchitecture which resembled 
more closely that of endogenous islets [346,347] and reduced islet death compared to the 
transplant with islets only [345]. Together, these studies highlight that the presence of MSCs 
during islet culture as well as transplantation might be required to benefit optimally from the 
multipotent cells. Finally, although allogeneic MSCs were believed to be immune privileged, 
recent evidence proposes that these cells can be recognized by the innate and adaptive immune 
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system [348]. Still, these cells have numerous immunomodulatory properties when exposed to 
an inflammatory microenvironment. To date, evidence shows that MSCs have 
immunoregulatory effects on T cells by inhibiting both T-cell proliferation, cytotoxic T-cell 
activity and decreasing IFN-γ production [349,350]. Furthermore, the immunomodulatory 
capacity of MSCs seems to involve the cleavage of CD25 from the surface of T cells by matrix 
metalloproteinase (MMP)-2 and -9, thereby attenuating T-cell responses to IL2 [351,352]. 
MSCs can also modulate several players of the innate immune system like a complement, toll-
like receptor (TLR) cascades, macrophages, DCs, and NK cells [353]. In islet cell 
transplantation, MSCs can alleviate allorejection by exerting suppressive effects through 
various T-cell subsets and DCs [354]. In fact, MSCs can shift the Th and cytotoxic T-cell 
balance and reduce the numbers of naive and memory T cells in peripheral blood after islet cell 
transplantation [354]. MSCs can also promote long-term islet allograft survival in the presence 
of short-term immunosuppression across a full MHC-mismatch in chemically-induced diabetic 
rats by promoting the generation of IL10-secreting Tregs [355]. Based on these encouraging 
findings, MSCs have found their way to the patient and have been under investigation as 
adjunctive therapy in the transplantation setting of islets (ClinicalTrials.gov Identifier: 
NCT00646724, NCT02384018) or as immunomodulatory therapy with the intention to reset 
the autoimmune system in (new-onset) T1D patients (ClinicalTrials.gov Identifier: 
NCT00690066). 
 
1.3.3.4.4.2 Multipotent adult progenitor cells 
Multipotent adult progenitor cells (MAPCs), which can be derived specifically from adult bone 
marrow but also from muscle and brain from human and/or rodent donors, are non-
hematopoietic, non-endothelial stem cells that have the potential to differentiate into cells with 
meso-, neuroecto- and endodermal (liver, lung and gut, respectively) characteristics in vitro and 
upon transplantation [356–358]. In this context, they are equivalent to ESCs and distinctive 
from MSCs, which can also be isolated from bone marrow. It has been postulated that MAPCs 
could be more primitive cells than MSCs; however, the potential association between MSCs 
and MAPC has yet to be recognized. MAPCs can be positive for telomerase, Oct3A (Oct3/4) 
or a combination thereof. As such, these cells can expand long term under stringent culture 
conditions without genetic instability, and can be administered without tissue matching. 
As ESCs and iPSCs, MAPCs can be sequentially committed to the formation of definitive 
endoderm, pancreatic endoderm, and beta-cell-like cells in vitro. The differentiation protocol 
made use of high concentrations of Activin A, a shh inhibitor, and optionally bone 
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morphogenetic protein 4 (BMP4), subsequently EGF or hepatocyte growth factor (HGF) or 
both to produce cells with increased neurogenin 3 (Ngn3) expression which after final exposure 
to nicotinamide and/or exendin-4 developed into insulin-positive cells [359]. When the mixed 
progeny containing a small fraction of glucose-responsive insulin-producing cells was 
implanted in vivo under the kidney capsule of chemically-induced diabetic 
immunocompromised mice it further matured and permanently reversed hyperglycemia [359]. 
Like MSCs, MAPCs can promote tissue repair and healing and induce neo-angiogenesis, 
possibly by delivering pro-angiogenic factors that activate/recruit endogenous vascular cells 
and that seem to be specifically tailored to the immediate needs of the damaged tissue [360–
363]. 
Although not yet established in the condition of islet cell transplantation, MAPCs behave non-
immunogenic and possess potent immunomodulatory effects on allogeneic T-cell responses 
[364]. Likewise, these cells can suppress T-cell proliferation and Th1 and Th17 cytokine 
secretion while improving antiinflammatory IL10 production and favoring Treg proliferation. 
Interestingly, MAPCs can downregulate autoreactive effector T-cell function from T1D 
patients [365,366]. Currently, clinical-grade large scale-expanded MAPCs, MultiStem®, are 
being evaluated in a number of phase 1/2 clinical trials in patients with ischemic stroke, 
ulcerative colitis, acute myocardial infarction, and for the prevention of graft versus host disease 
(GVHD) in patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT). In 
prevention of GVHD, both single- and multiple-dose infusions of MultiStem® were well-
tolerated, and a low incidence of severe acute GVHD was observed [367]. The fine-tuning of 
stem-cell products in order to achieve consistent and safe products for off-the-shelf use is 
currently a major effort of process development. 
 
1.3.3.4.4.3 Endothelial progenitor cells 
Human endothelial progenitor cells (EPCs) have been defined as circulating cells that express 
a number of cell surface markers similar to those expressed by vascular endothelial cells (ECs), 
adhere to the endothelium at sites of damaged tissue or ischemia, and take part in vascular 
formation, repair and remodeling, especially after transplantation [368,369]. This cell type has 
enormous potential in the treatment of ischemic diseases such as myocardial and hindlimb 
ischemia [370,371].Although these progenitor cells have the ability to integrate into new 
developing blood vessels, they can also deliver humoral factors that may recruit accessory cells 
to impact beneficially on blood vessel remodeling, and elicit pro-survival mechanisms. Several 
studies have examined the potential of EPCs in improving outcomes in islet cell transplantation. 
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Co-transplantation of pre-cultured islets with EPCs accelerated the engraftment process in a 
marginal mass of islets in a syngeneic murine transplant model. The rapid revascularization by 
EPC co-transplantation was suggested to induce better graft perfusion and recovery from 
hypoxia. Moreover, soluble factors released by EPCs in islet culture were shown to modulate 
the expression of the beta-cell gap junction protein connexin 36 (Cx36), thereby favorably 
affecting glucose-stimulated insulin release in vitro [372]. Indeed, Cx36-dependent signaling 
seems necessary for proper beta-cell function, particularly for the pulsatility of intracellular 
Ca2+ and glucose-stimulated insulin secretion [373]. Other studies have demonstrated very 
similar results in improving islet revascularization after co-transplanting with EPCs [374–377]. 
In the transplant setting, it is common knowledge that matures donor-derived ECs contribute to 
the blood vessel formation in the graft [378,379] along with the ingrowth of recipient-derived 
ECs and bone marrow-derived cells [380,381].When EPCs from green fluorescent protein 
(GFP) transgenic rats were co-transplanted with syngeneic islets into the portal vein, they 
triggered neo-angiogenesis from host origin in infused islets. Moreover, the EPC-secreted pro-
angiogenic factors (e.g. VEGF-A) prompted higher endothelial thickness and vessel density, 
leading to long-lasting normal blood glucose control in chemically-induced diabetic rats [374]. 
Another study, however, demonstrated that EPCs derived from bone marrow improved islet 
graft organization and promoted graft revascularization not only through paracrine effects but 
also via incorporation into the host vascular system [375]. Just now, co-transplantation of 
human blood outgrowth endothelial cells (BOECs) with islets in a mouse model of diabetes 
resulted in a significant and specific enhancement of glycemic control with superior C-peptide 
responses. Moreover, these cells reduced beta-cell death and increased beta-cell proliferation 
as well as graft-vessel and beta-cell volume, irrespective of the surgical techniques using a 
blood clot-dependent or -independent tubing system [376,382]. Interestingly, EPCs not only 
have the capacity to improve islet graft revascularization but these cells seem to be crucial for 
the activation of endogenous pancreatic stem cells during islet regeneration [383].These data 
further support the use of EPCs in clinical studies that aim to improve current islet cell 
transplantation protocols. 
 
1.3.3.4.4.4 Neural crest stem cells 
The neural crest is a transient embryonic structure in vertebrates that initially generates neural 
crest stem cells (NCSCs) which then migrate throughout the body to produce a diverse array of 
mature tissue types. Due to the rarity of adult NCSCs as well as several ethical and technical 
issues surrounding the isolation of early embryonic tissues, biologic studies of human NCSCs 
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are extremely challenging [384]. However, this stem-cell population can also be isolated from 
hair follicles [385,386] and the oral mucosa of human origin [387]. These cells can proliferate 
in vitro and can be directed towards peripheral nervous system lineages (e.g. peripheral neurons, 
Schwann cells) and mesenchymal lineages (e.g. smooth muscle, adipogenic, osteogenic and 
chondrogenic cells)[388]. Recent work demonstrated that NCSCs are also capable of 
considerably improving islet function by promoting beta-cell proliferation [389]. In addition, 
when mouse islet cells were cultured in intimate contact with NCSCs, more than 35% of the 
islet beta cells showed increased cell cycle activity compared to control islets cultured without 
NCSCs [390]. On the other hand, exposure of human islets to NCSCs induced higher 
proliferation in vitro and in vivo. Moreover, NCSC-exposed human islet grafts in vivo had much 
higher neural and vascular densities with substantially higher blood perfusion and oxygen 
tension in the newly formed blood vessels 4 weeks after transplantation [391]. These results 
were explained by a combination of improved recipient blood vessel in-growth and expansion 
of donor blood vessels. In summary, exposure of islets to NCSCs was shown to stimulate beta-
cell proliferation and improve both neural and vascular engraftment of transplanted islets.
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2.1  OVERALL OBJECTIVEIn T1D patients the pancreatic insulin-producing beta cells are 
selectively destroyed by the immune system, leading to an impaired glucose metabolism. 
The steep increase in the incidence of this chronic autoimmune disease especially in young 
children in the last decades raises serious concerns. To date, insulin therapy is considered 
the gold standard for the treatment of T1D. Nevertheless, limitations persist, such as the 
frequent episodes of hypoglycemia, and the chronic micro- and macrovascular 
complications. Islet cell transplantation offers an alternative treatment for T1D patients, 
specifically for those with hypoglycemic unawareness following insulin administration. 
Despite the improved outcome of islet cell transplantation over the last few years, 
drawbacks remain, such as a limited supply of cadaveric donors, the necessity of several 
donors for a single transplantation, and (immediate) graft failure through metabolic 
pressure, continued autoimmunity, alloimmunity, high concentrations of 
immunosuppressive drugs, and oxidative stress caused by hypoxia or due to cytokine 
exposure  
 
In this thesis, we propose that in the long-term, tolerogenic antigen-based and beta-cell 
replacement/regenerative approaches could be promising in both blocking beta-cell 
autoimmunity to prevent continued beta-cell destruction and boosting beta-cell function and 
revascularization to restore sustainable insulin regulation. 
 
2.2 SPECIFIC AIMS 
2.2.1 Restoration of self-tolerance after islet cell transplantation 
A cure for longstanding T1D patients, which have hardly any functional beta-cell mass left, 
implies replacement of the destroyed beta cells and reinstatement of tolerance to islet antigens. 
Our group has demonstrated oral tolerance induction to islet antigens delivered by genetically-
modified L. lactis. We reached approximately 60% of new-onset diabetes remission in NOD 
mice when the L. lactis-based vaccine producing human proinsulin along with pro-tolerogenic 
IL10 was combined with a short course of sub-therapeutic doses of anti-CD3 mAbs. Here, we 
want to test whether our therapeutic intervention also works in longstanding autoimmune 
diabetic mice after islet supplementation.  
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2.2.2 Improvement of beta-cell engraftment 
MAPC have been shown to promote tissue repair and healing and induce neo-angiogenesis, 
possibly by delivering angiogenic growth factors that activate/recruit endogenous vascular cells 
and that seem to be specifically tailored to the immediate needs of the injured tissue. In vivo, 
these cells are short-lived as they experience only a minimally prolonged residence time. 
Moreover, in contrast to other cell types, MAPC can be expanded long-term (for >80 population 
doublings) without genetic instability, and administered without tissue matching, making them 
into an optimal stem cell product for routine clinical use (MultiStem®, Athersys Inc., 
Cleveland). Therefore, we aim in this thesis to assess the therapeutic efficacy of co-
transplantation of undifferentiated human MAPC with mouse islets as separate or composite 
pellets in a syngeneic marginal mass islet cell transplantation model. 
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3.1 RESTORATION OF SELF-TOLERANCE AFTER ISLET TRANSPLANTATION 
3.1.1 Animals 
NOD mice, originally obtained from Professor Wu (Department of Endocrinology, Peking 
Union Medical College hospital, Beijing, China), were inbred in our animal facility since 1989 
and kept under semi-barrier conditions. At regular time intervals, mice were screened for 
glucosuria and consequently considered diabetic if nonfasting blood glucose concentrations 
exceeded 200 mg/dl for 2 consecutive days (AccuCheck, Roche Diagnostics Belgium, 
Vilvoorde, Belgium). Animals were kept under insulin pellets (Linbit™; LinShin Canada, Inc., 
Ontario, Canada) until the day of islet implantation designated as day 0. Animals were handled 
in accordance with the Guide for the care and use of laboratory animals, Eighth edition (2011) 
as well as Katholieke Universiteit Leuven (KULEUVEN, Leuven, Belgium) Animal Care and 
Use Guidelines.  
 
3.1.2 Islet isolation and transplantation 
Islets were isolated from 2-3-week-old prediabetic male NOD mice as described [392]. Density 
gradient centrifugation followed by handpicking of islets certified that preparations were highly 
enriched in islets and had an accurate determination of islet number. For transplantation, 500 
freshly isolated islets were grafted beneath the left renal capsule of each diabetic NOD recipient 
(between 0 and 4 weeks after diabetes diagnosis). Transplantation was considered successful if 
the nonfasting blood glucose concentration returned to normal (< 200 mg/dl) within 24 hours 
after surgery. Weight and blood glucose concentrations from tail were monitored three times a 
week after transplantation with an AccuCheck glucometer. Graft survival was calculated as the 
number of days before diabetes recurrence. The day of diabetes recurrence was defined as the 
first of 2 consecutive days of nonfasting blood glucose concentrations >250 mg/ml. Mice were 
killed after confirmation of diabetes recurrence for metabolic, histological and flow cytometric 
analysis 6 weeks after initiation of treatment. 
 
3.1.3 L. lactis culture 
Genetically-modified L. lactis strain secreting human proinsulin with human IL10 were 
generated by transformation of the IL10-secreting sAGX0037 strain with proinsulin-encoding 
plasmid [74]. The amino acid sequence for proinsulin was retrieved from the National Center 
for Biotechnology Information (NC_00011). This strain was grown in GM17TE medium (i.e. 
M17 broth supplemented with 0.5% glucose, 200 µM thymidine (Sigma) and 5 µg/ml 
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erythromycin (Sigma, St. Louis, MO)). Stock suspensions were stored in -80°C in 50% glycerol 
(Merck) in cryovials. For intragastric inoculations, stock suspensions were diluted 1000-fold in 
growth medium and incubated for 16 hrs at 30°C, reaching a saturation density of 2 × 109 colony 
forming units (CFU)/ml. Bacteria were harvested by centrifugation and concentrated 10-fold in 
BM9 medium. Treatment dose consisted of 100 µl of this suspension. 
 
3.1.4 Treatment groups 
Two different treatment regimens were used. In the first regimen (early), therapy started prior 
to islet implantation (d–5 to d–1) and continued for a total of 6 weeks. In the second regimen 
(delayed), therapy started at the time of islet implantation (d0). Hamster anti-mouse CD3 mAbs 
(clone 145-2C11, Bio X Cell, West Lebanon, NH) were administered iv (2.5 µg/d; total of 12.5 
µg) for 5 consecutive days. Genetically-modified L. lactis bacteria were given by intragastric 
inoculation (2 × 109 CFU/d) 5 times per week for a period of 6 weeks.  
 
3.1.5 Metabolic β-cell function 
Random C-peptide concentrations in sera were measured by ELISA (Merck Millipore, 
Massachusetts, MA). Pancreata were harvested for histological analyses (see 3.1.6) and/or for 
insulin content determination by ELISA (Mercodia, Uppsala, Sweden) after acid/ethanol 
extraction. 
 
3.1.6 Histology and confocal immunofluorescence 
Graft-bearing kidneys were fixed in 10% buffered formalin and embedded in paraffin at the 
time of diabetes recurrence or at selected time points after islet implantation. Sections were 
stained with hematoxylin and eosin. Insulin staining was performed using a guinea pig anti-
insulin primary antibody (#A0564; Dako Belgium nv/sa, Heverlee, Belgium) and an AF88-
conjugated goat anti-guinea pig IgG (Molecular Probes, Thermo Fisher Scientific, Waltham, 
MA) secondary antibody. Beta-cell mass of the islet grafts was done by Z-stack confocal 
microscopy analysis, capturing five different focal planes from each graft and then quantifying 
the insulin+ volume (µm3) at Volocity software. 
Immunofluorescence imaging on graft-bearing kidneys snap-frozen in Tissue-Tek OCT 
compound (Sakura Fineteck, Torrance, CA) was used to determine immune populations in the 
graft. Using cryomicrotome and Superfrost Plus slides (Fisher Scientific, Thermo Fischer 
Scientific), 6-μm tissue sections were cut. Sections were stained by the use of antibodies 
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directed to CD4 (clone RM4-5; #550280, BD Biosciences, Erembodegem, Belgium) or CD8a 
(clone 53-6.7; #550281, BD Biosciences) followed by AF488-conjugated goat anti-rat IgG as 
secondary antibody. Slides were imaged using a Sarastro 2000 confocal laser scanning 
microscope (Molecular Dynamics, Sunnyvale, CA). Obtained images were adjusted linearly for 
presentation using ImageJ (free software that can be downloaded at http://rsbweb.nih.gov/ij/). 
 
3.1.7 Flow cytometry 
Single cell suspensions were prepared from lymphoid organs (i.e. spleen, pancreatic draining 
lymph nodes, and kidney draining lymph nodes) by mechanical disruption. Cell suspensions 
were rendered free of red blood cells by exposure to a solution containing 0.83% NH4Cl. Cells 
were stained with directly conjugated Abs against CD4, CD8α, CD25, CD44, CD62L, CD69 
and matching isotype controls (eBioscience, San Diego, SA). Intracellular stainings for Foxp3 
and CTLA4 were also performed according to eBioscience’s instructions. Samples (>10,000 
cells) were acquired on a Gallios™ (Beckman Coulter, Suarlée, Belgium) or BD Canto II (BD 
Biosciences) flow cytometer and data were analyzed with either Kaluza™ (Beckman Coulter) 
or FlowJo (Tree Star Inc., Ashland, OR) software. 
 
3.1.8 Statistics 
Statistical analyses were performed with GraphPad Prism software (La Jolla, San Diego, CA). 
Kaplan-Meier analysis was performed for diabetes-free survival determination, and differences 
were assessed with the Mantel-Cox log-rank test. FACS, ELISA and insulin content data were 
analyzed for statistical significance by either Mann-Whitney U-test or Kruskal-Wallis test with 
Dunn’s correction, unless indicated otherwise; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P 
< 0.0001  
 
3.2 IMPROVEMENT OF BETA-CELL ENGRAFTMENT 
3.2.1 Animals 
C57BL/6 mice (purchased from Charles River, L’ Arbresle, France) were used as islet donors 
and transplant recipients in all procedures. The mice were handled in accordance with the Guide 
for the care and use of laboratory animals, Eighth edition (2011) as well as Katholieke 
Universiteit Leuven (KULEUVEN, Leuven, Belgium) Animal Care and Use Guidelines. 
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3.2.2 Preparation and characterization of human MAPC 
Human MAPC (n=2) used in this study were isolated by ReGenesys BVBA (Athersys Inc. 
affiliate in Heverlee, Belgium) from bone marrow of a 30-year-old female and a 45-year-old 
male volunteer, with informed consent and ethical approval. Isolation and culture of the cells 
were carried out as described [393]. Human MAPC were expanded on the Quantum cell 
expansion system (Terumo BCT, Lakewood, CO). This closed automated culture system is 
comprised of a synthetic hollow-fiber bioreactor connected to sterile closed-loop, computer-
controlled media and gas exchangers. The bioreactor contains ~11,000 fibers generating an 
expansion surface area of 2.1 m². After coating the bioreactor with fibronectin, cells were 
seeded on the inside of the hollow fibers and expanded in MAPC culture medium. Cells were 
harvested after 5-6 days using trypsin/EDTA. 
Phenotypic analysis of the human MAPC was performed using fluorochrome-conjugated 
antibodies recognizing a cluster of differentiation 3 (CD3), CD31, CD34, CD40, CD44, CD86, 
CD105, Flk1, HLA-ABC, and HLA-DR (eBioscience). The acquisition was done by using a 
Gallios™ multicolor flow cytometer (Beckman Coulter). For analysis of the samples, FlowJo 
(Tree Star Inc.) software was used.  
Cell-free supernatants were assayed for human basic fibroblast growth factor (bFGF), C-
reactive protein (CRP), eotaxin, eotaxin-3, soluble fms-like tyrosine kinase 1 (sFlt1), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), soluble intracellular adhesion 
molecule-1 (sICAM-1), IFN-γ, IL1α, IL1β, IL10, IL12 p70, IL12/IL23p40, IL13, IL15, IL16, 
IL17A, IL2, IL4, IL5, IL6, IL7, IL8, IP-10, monocyte chemoattractant protein-1 (MCP-), 
MCP4, macrophage-derived chemokine (MDC), macrophage inflammatory protein-1α ( MIP-
α), MIP-β, placental growth factor (PlGF), serum amyloid A (SAA), thymus- and activation-
regulated chemokine (TARC), Tie2, TNF-α, TNF-β, soluble vascular cell adhesion molecule-
1 (sVCAM-1), VEGF-A, VEGF-C, and VEGF-D by multiplex electrochemiluminescence 
(Meso Scale Discovery, Rockville, MD) as per manufacturer’s protocol. 
The angiogenic potential of human MAPC was examined in the chick chorioallantoic 
membrane (CAM) as described [394]. 
 
3.2.3 Marginal mass syngeneic islet cell transplantation diabetes model 
To induce diabetes in recipients, a single intravenous injection of alloxan (90 mg/kg; Sigma) 
was administered to male C57BL/6 mice, and animals were considered to be diabetic after two 
consecutive non-fasting tail vein blood glucose concentrations of ≥200 mg/dl, measured by an 
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AccuCheck Glucometer (Roche Diagnostics). Before transplantation, islets from 2-3 week-old 
C57BL/6 mice isolated by collagenase digestion were washed, counted, and in some cases 
mixed with human MAPC [392]. Thereafter, the cellular pellets were transferred to silicon 
microtubing (BD Biosciences), centrifuged for 5 minutes at 1500 rpm. During transplantation, 
the mice were anesthetized, and the left kidney was exposed by a lumbar incision. Diabetic 
recipient mice were given 150 islets alone, 150 islets and 2.5 × 105 human MAPC as separate 
pellets (SEP) or 150 islets and 2.5 × 105 human MAPC as a composite pellet (MIX) under the 
renal capsule. Non-fasting blood glucose levels from the tail vein of each recipient were 
measured daily during the first week post-transplantation and thereafter three times weekly. 
Mice were considered cured when having blood glucose levels <200 mg/dl after 3 consecutive 
measurements. All islet cell transplantations were performed at random in all experimental 
groups. On week 2 and 5 after islet cell transplantation, graft-bearing kidneys were removed 
and fixed in 4% formaldehyde followed by paraffin embedding or were used for RNA isolation. 
 
3.2.4 Physiological studies 
Glucose tolerance tests were performed after a 16-hour fast. Mice were injected IP with D-
glucose (2 g/kg body weight), and blood glucose levels were measured at the indicated times. 
For serum insulin and C-peptide determination, blood was collected from the saphenous vein. 
Serum was isolated by centrifugation, levels of pancreatic hormones were determined by 
ultrasensitive enzyme-linked immunosorbent assay (ELISA) kits (Mercodia or Merck 
Millipore).  
 
3.2.5 Morphometry and immunohistochemistry 
Graft-bearing kidneys were embedded in paraffin, and 6 µm sections were obtained from the 
total graft area. Insulin (guinea-pig, #A0564, Dako Belgium nv/sa), glucagon (mouse, #G2654, 
Sigma), somatostatin (rat, #ab30788, Abcam, Cambridge, UK), endomucin (rat, #sc-65495, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA) and α-smooth muscle actin (SMA) (goat, 
#EB06450, Everest Biotech Ltd, Oxfordshire, UK) stainings were used to evaluate beta-cell 
mass and blood vessel density respectively with the aid of the Ventana system (Ventana 
Medical Systems Inc., Tucson, AZ). The endomucin as well as α-SMA antibody is 
recommended for detection of endomucin or α-SMA respectively of mouse and not human 
origin. 
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For quantification of the beta-cell and blood vessel volumes, all images were captured using a 
Nikon Eclipse TE2000-E microscope using a 40× magnification objective and the large image-
capture feature so that the entire graft area of each section could be pictured at once. Insulin+, 
glucagon+ and somatostatin+ areas as well as endomucin+ areas within the endocrine 
compartment of the islet graft were measured semi-automatically by ImageJ/Fiji software on 
approximately 15% (i.e. every fifth section) of the total graft as described [376]. The vessel/beta 
cells ratio was calculated as (blood vessel area/insulin+ area) × 100%. Vessel density was 
calculated as the number of intra-islet vessels per mm2.  
 
3.2.6 Quantitative PCR 
Islet graft RNA was isolated using the PureYield™ RNA Midiprep System (Promega, Madison, 
WI) as described [394], and a 1-µg aliquot was reverse transcribed into cDNA (Superscript II; 
Life Technologies, Carlsbad, CA). cDNA was then subjected to quantitative PCR using gene-
specific forward and reverse primers (own design or purchased from Integrated DNA 
Technologies, Coralville, IA (CD31/PECAM-1) or Thermo Fisher Scientific, Waltham, MA 
(α-SMA)) using either Fast SYBR® Green Master Mix or a gene-specific TaqMan® probe in 
combination with TaqMan® Fast Universal Master Mix (Life Technologies). Primer and probes 
sequences are listed in table 1. Each quantitative reaction was carried out in duplicate or 
triplicate, and islet grafts from 6-11 mice of each experimental group were independently tested. 
Relative mRNA expression value is calculated using the ∆∆Ct method. All samples were 
normalized to the average of Actine, HPRT and RPL27 as housekeeping genes. Background 
amounts of each target gene were calculated from the non-grafted kidney. Results are expressed 
as the mean ± SEM.  
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Table 1: Primer and probe characteristics 
Target Sequence 
Insulin 
F 5’-CCGGGAGCAGGTGACCTT-3’ 
R 5’-GATCTACAATGCCACGCTTCTG-3’ 
P 5’-AGACCTTGGCACTGGAGGTGGCC-3’ 
Glucagon 
F 5’-AACAACATTGCCAAACGTCA-3’ 
R 5’-TGGTGCTCATCTCGTCAGAG-3’ 
SYBR 
Somatostatin 
F 5’-GGAAACAGGAACTGGCCAAGT-3’ 
R 5’-GGGTTCGAGTTGGCAGACC-3’ 
SYBR 
CD31/PECAM-1 
F 5’-GCATGTCTTTTATGATCTCAGAC-3’ 
R 5’-CATCGGCAAAGTGGTCAAGA-3’ 
SYBR 
F: forward; R: reverse; P; probe; SYBR: Fast SYBR® Green 
3.2.7 Statistical analysis 
Statistics were calculated with Prism software 5.0 (GraphPad Software Inc.). The chi-square 
test was applied to identify the significance of the difference between diabetes reversal rates 
between different groups. All numerical values were presented as the mean ± SEM. 
Significance was determined using Mann-Whitney U-test or Kruskal-Wallis test, and a value 
of P<0.05 was considered significant.
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CHAPTER 4 
 
 
 
 
 
RESTORATION OF SELF-TOLERANCE AFTER ISLET TRANSPLANTATION2 
                                                 
2 based on João Paulo Monteiro Carvalho Mori Cunha, Dana Cook, Giuliana Ventriglia, Guido Sebastiani, 
Francesca Mancarella, John Kappler, Philippa Marrack, Lothar Steidler, Pieter Rottiers, Francesco Dotta, Conny 
Gysemans, Chantal Mathieu. Induction of active tolerance after islet cell transplantation in longstanding diabetic 
NOD mice after L.lactis-based vaccine combined with low-dose anti-CD3: a matter of timing. Manuscript in 
preparation 
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4.1 INTRODUCTION 
T1D is a chronic autoimmune pathology characterized by selective destruction of the insulin-
producing beta cells in the pancreas [2]. Until today exogenous insulin administration remains 
the standard treatment, however, with often undesirable recurrent episodes of hypoglycemia 
and long-term macro- and microvascular complications. Especially for T1D patients with 
hypoglycemia unawareness, beta-cell replacement in the modality of intraportal allogeneic islet 
transplantation has been shown to provide a significant improvement in glycemic control with 
the eradication of severe hypoglycemic episodes [9,395]. Most islet transplant recipients at 
qualified centers reach insulin independence 1 year after islet implantation. Although the long-
term outcome of clinical islet transplantation improved substantially since the introduction of 
the Edmonton protocol [239,396], adverse events are often related to the immunosuppressive 
drugs used to avoid immune responses to alloantigens and recurrence of autoimmunity. 
 
Currently, most islet transplant recipients receive an induction immunosuppression therapy 
with biologicals like ATG or anti-CD25, followed by glucocorticoid-free maintenance 
schedules consisting of tacrolimus and MMF or sirolimus [239,397]. Another approach to 
induction therapy includes the use of either anti-CD3 mAbs [398] or a mixture of rATG or 
alemtuzumab combined with etanercept (anti-TNF-α) [399,400]. These novel regimens with 
anti-CD25 or ATG preferentially deplete lymphocytes, but maintain or increase Treg 
frequencies and functionality, and diminish cytokine toxicity on the implanted islets. 
Unfortunately, lymphodepletion strategies cause “cytokine storm” in the initial days after 
administration, including the release of IL7 and IL15 which can induce homeostatic expansion 
of islet-specific autoreactive T cells with effector memory phenotype [401]. Also, preclinical 
data demonstrated that recurrent autoimmune diabetes is mainly driven by IGRP206–214/H2K
d 
(NRP-V7)-reactive T cells from the memory pool [402]. This also implies that local islet 
antigen expression, in addition to MHC class I expression is indispensable for the increase of 
autoreactive CD8+ T cells into islet grafts [403]. These findings underscore the importance of 
tackling autoreactive T-cell memory after beta-cell replacement therapy. The implementation 
of induction therapy prior to and at the moment of islet implantation clearly improved 5-year 
insulin independence when combined with maintenance regimens [399] but also emphasized 
the need for immunomodulatory regimens which aim at inducing tolerance to both foreign and 
beta-cell antigens in islet transplant recipients. 
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Several preclinical studies have documented that combining lymphodepletion with other 
modalities may induce peripheral tolerance [404–407], although this has yet to be fully 
accomplished in men. Emphasis is put on peptide-specific strategies, concentrating on the 
tolerogenic delivery of beta-cell antigens and non-mitogenic anti-CD3, which specifically 
targets the TCR in the absence of costimulatory signals. In this context, we reached 
approximately 60% of new-onset diabetes remission in NOD mice when genetically-modified 
L. lactis-based vaccines producing either human proinsulin or a GAD65 peptide along with 
IL10 was combined with a short course of sub-therapeutic doses of anti-CD3 mAbs [74,201]. 
In this current study, we tested whether our antigen-specific intervention could also work in 
longstanding autoimmune diabetic mice after islet supplementation. 
 
4.2 EXPERIMENTAL DESIGN 
Recipients for the islet cell transplantation experiments were severely diabetic male NOD mice, 
usually over 20 weeks of age, which presented blood glucose concentrations exceeding 200 
mg/dl and had diabetes duration between 0 and 4 weeks after diagnosis. These mice received 
sc implantation with insulin pellets (LinBit™) to prevent death. Transplants (500 insulitis-free 
islets isolated from 2-3-week-old NOD mice) were placed unilaterally under the left kidney 
capsule to facilitate histological examination. Mice were treated either prior to islet 
implantation (early regimen from d−5 to −1: Figure 4.1A) or at the time of transplantation 
(delayed regimen from d0: Figure 4.1B). Treatment regimens consisted out of hamster anti-
mouse anti-CD3 mAbs (clone 145-2C11) for 5 consecutive days at low doses of 2.5 µg per day 
and were given simultaneously with genetically-modified L. lactis bacteria secreting human 
proinsulin and IL10 (LL-PINS+IL10; 2 × 109 CFU/d) 5 times weekly for a total period of 6 
weeks. 
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Figure 4.1. Treatment regimens in NOD islet recipient mice. New-onset diabetic NOD mice were sc implanted 
with insulin pellets and kept for an additional 1 – 3 weeks after diagnosis. Animals were injected with low-dose 
CD3 mAbs (clone 145-2C11; 2.5 µg/d iv) for 5 consecutive days prior to (A; early regimen) or at the time of islet 
cell transplantation (B; delayed regimen). Intragastric administration of genetically-modified L. lactis bacteria 
secreting proinsulin and IL10 (LL-PINS+IL10; 2 × 109 CFU/d 5 times weekly) started together with anti-CD3 
induction therapy and persisted for a total period of 6 weeks. Weight and blood glucose concentrations were 
measured three times weekly. 
 
4.3 RESULTS 
4.3.1 Pharmacodynamic profile of anti-CD3 
We first examined the pharmacokinetics of anti-CD3 (clone 145-2C11) on different lymphocyte 
frequencies (CD3+, CD4+ and CD8+ T cells) in new-onset diabetic NOD mice (without islet 
supplementation) by multicolor flow cytometry. We assessed the splenic T-cell proportions 
prior to (day 0) and weekly after dosing (day 7, 14, 21 and 28). Mice receiving total of 12.5 µg 
of anti-CD3 mAbs (clone 145-2C11; 2.5 µg/d iv for 5 consecutive days) had 7 days after anti-
CD3 injection significantly lower proportions of CD3+ T cells in the spleen, due to selective 
depletion of CD4+ T cells but not of CD8+ T cells which remained fairly stable after anti-CD3 
injection (Figure 4.2A). 
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Earlier studies established that anti-CD3 mAbs are particularly effective at controlling recently 
activated effector T cells [408]. In our study, we found that although bulk CD4+ and CD8+ T 
cells recovered by day 21 after anti-CD3 injection, but the distribution of CD4+ and CD8+ T-
cell populations continued to be modified (Figure 4.2B and C). In detail, anti-CD3 augmented 
the T-cell fraction with a putative effector/memory phenotype (CD69+CD44– and CD69–
CD44+) in especially CD4+ but also in CD8+ T cells in the spleen. 
 
 
Figure 4.2. Low-dose anti-CD3 mAb treatment transiently reduces splenic T-cell frequencies. NOD mice were 
treated with anti-CD3 mAb (2.5 µg/d i.v., day 0 – 4). (A) T-cell subset frequencies in the spleen were determined 
by flow cytometry and displayed as a percentage of live cells. The frequencies of naive (CD44–CD69–), recently 
activated (CD44+CD69+) and memory (CD44+CD69–) T cells were determined and plotted as percentage of CD4+ 
(B) or CD8+ (C) T cells. Symbols represent values of individual mice (n=4), the line connects the mean per time 
point. 
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4.3.2 Prevention of autoimmune diabetes recurrence by L. lactis-based therapy combined 
with low-dose anti-CD3 depends on the timing of drug administration and diabetes duration 
Based on the time kinetics of anti-CD3 mAbs, we hypothesized that induction therapy with 
low-dose anti-CD3 alone or combined with genetically-modified L. lactis secreting proinsulin 
and IL10 initiated prior to islet implantation (d−5 to −1: Figure 4.1A) could prevent 
autoimmune diabetes recurrence as lymphodepletion after anti-CD3 injection  was then almost 
at its highest level (Figure 4.2). NOD islet recipient mice (0 to 4 weeks after diabetes diagnosis), 
left untreated, demonstrated autoimmune disease recurrence in all animals (mean survival time 
= 8 days). When anti-CD3 either alone or combined with the L. lactis-based vaccine was 
administered prior to islet implantation only 17 and 25% of mice respectively evaded disease 
recurrence (Figure 4.3A). 
We reasoned that early induction immunosuppression might prevent graft destruction in the 
immediate post-transplantation period but might not be able to inhibit specifically the strong 
memory autoimmune responses directed against the newly implanted islets (antigens). 
Therefore, we designed a regimen in which therapy started at the time of islet implantation 
(Figure 4.2B). With this delayed initiation of therapy, 34% of anti-CD3-treated NOD islet 
recipient mice and 56% of combination therapy-treated animals remained normoglycemic 
during therapy and even 14 weeks after transplantation (Figure 4.3B). These data put forward 
that the crucial period for the therapeutic efficacy of anti-CD3 therapy either alone or combined 
with L. lactis-based vaccine is not prior to islet implantation. 
 
Figure 4.3. The start of L. lactis-based therapy in diabetic NOD mice determines the therapeutic outcome. NOD 
islet recipient mice were treated with anti-CD3 alone (mono) or combined with L. lactis-based vaccine (combi) 5 
consecutive days prior to (early) (A) or at the time of islet implantation (B). Kaplan-Meyer curves where the 
endpoint was sacrifice were compared with the log-rank test. **P < 0.01; ****P < 0.0001 vs. untreated controls. 
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As NOD islet recipient mice had different duration of diabetes (between 0 to 4 weeks after 
diabetes diagnosis) at the moment of islet implantation, we also studied whether this parameter 
would have an effect on the therapeutic outcome. Interestingly, the efficiency to prevent 
autoimmune diabetes recurrence diminished in anti-CD3-treated mice with diabetes duration 
(50, 60, 37, 20 and 14% in mice 0, 1, 2, 3 and 4 weeks post-diagnosis).  
In contrast, combination therapy-treated mice were significantly better at avoiding autoimmune 
disease recurrence and much less influenced by diabetes duration (86, 67, 53, 42 and 60% in 
mice 0, 1, 2, 3 and 4 weeks post diagnosis)(Figure 4.4).  
 
Figure 4.4. Time after diabetes diagnosis determines therapeutic success of the L.lactis-based immunomodulatory 
therapy given at the time of islet implantation. Diabetic NOD mice (diabetes duration between 0 – 4 weeks) were 
transplanted with islets from NOD donors (syngeneic) and treated with anti-CD3 alone (2.5 µg/d iv for 5 
consecutive days) with LL-PINS+IL10 (2 × 109 CFU/d 5 days per week for 6 weeks). Kaplan-Meyer curves where 
the endpoint was sacrifice were compared with the log-rank test. ****P < 0.0001 vs. untreated controls. 
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4.3.3  L. lactis-based combination therapy preserves beta-cell function of the islet grafts and 
remaining endogenous islets 
The mechanisms by which our L. lactis-based therapy regimen may exert benefit might be two-
fold. First, the immunomodulatory regimen may offer better protection of the implanted islets 
from innate immune responses in the perioperative period, thereby maintaining islet graft 
function. Second, these regimens may alleviate recurrent autoimmunity directed at transplant 
islets by eliminating at least temporarily, the autoreactive T-cell compartment and by promoting 
antigen-specific Treg generation. 
In our study, we first observed that the random serum C-peptide concentrations 6 weeks after 
transplantation were higher at all time point after diabetes diagnosis in the ‘cured’ NOD islet 
recipient mice given either anti-CD3 or L. lactis-based combination therapy together with islet 
implantation compared to untreated animals (Figure 4.5A). This functional profile was mirrored 
by the beta-cell mass of the islet grafts as measured by confocal microscopy (data not shown). 
We also determined the endogenous beta-cell mass by analyzing the insulin content of the 
native pancreas. As expected, the pancreas from untreated and ‘non-cured’ animals given either 
anti-CD3 or L. lactis-based combination therapy had negligible concentrations of insulin 
(Figure 5.5B). Unexpectedly, long-term preservation of endogenous beta-cell mass was 
observed in the pancreatic islets of previously hyperglycemic recipients. Both anti-CD3 alone 
and L. lactis-based combination therapy protected the endogenous beta cells, although this 
decreased with diabetes duration (Figure 4.5B). These observations imply tht ‘cured’ treated 
NOD islet recipients with long-term diabetes duration rely exclusively on their newly implanted 
islets for proper glucose control. 
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Figure 4.5. Serum C-peptide concentrations and insulin content of the native pancreas 6 weeks after islet 
implantation in NOD recipient mice. Diabetic NOD mice (diabetes duration between 0 – 4 weeks) were 
transplanted with syngeneic islets and treated with anti-CD3 alone (mono; 2.5 µg/d iv for 5 consecutive days) with 
or without LL-PINS+IL10 (combi; 2 × 109 CFU/d 5 days per week for 6 weeks). (A) C-peptide concentrations 
were measured in serum from random-fed NOD islet recipients. (B) Total pancreatic insulin content in random-
fed NOD islet recipients. Crossed circles: untreated controls; white symbols: non-cured; black symbols: cured; 
triangles: monotherapy; squares: combination therapy.  
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4.3.4 Graft acceptance despite massive immune infiltration 
The kidney containing islet grafts from NOD recipient mice (2 weeks after diabetes diagnosis) 
that had been treated with anti-CD3 alone (mono) or combined with L. lactis-based antigen-
specific therapy (combi) was examined histologically 6 weeks after islet implantation. 
Untreated animals had almost completely destroyed islet grafts with striking lymphocytic 
infiltration, a characteristic of autoimmune diabetes recurrence (data not shown). Few intact 
islets were detected in the grafts. Similar histological characteristics were apparent in islet grafts 
retrieved from non-cured treated NOD recipient mice 6 weeks after islet implantation (data not 
shown). Despite mononuclear infiltration in both groups (untreated and treated), islet 
architecture was preserved in NOD recipient mice cured by anti-CD3 mono and combination 
therapy (Figure 4.6). Moreover, immunofluorescent analysis of the graft CD4 and CD8 staining 
showed analogous mononuclear accumulation around the grafted tissue in both treatment 
groups. Comparable histological observations were also found in NOD islet recipient mice with 
different diabetes duration at islet implantation (data not shown). 
Next, we examined at therapy discontinuation the distribution of insulin-producing beta cells 
and Tregs by histology in islet grafts of NOD recipient mice (2 weeks after diabetes diagnosis) 
treated with anti-CD3 alone (mono) or combined with L. lactis-based therapy (combi). 
Densities of Foxp3+ cells were markedly increased around islets in NOD recipient mice with 
accepted grafts compared to untreated controls, irrespective of therapy (Figure 4.6). However, 
also in the islet grafts of non-cured treated NOD recipient mice Foxp3+ cells were present at 
the site of extensive tissue damage (data not shown). We hypothesize that these Tregs may be 
largely outnumbered by antigen-experienced effector T cells. We speculate that regardless of 
success or failure in protecting the islet transplant, Tregs may persistently interact with effector 
T cells, but an imbalance in the numbers of Tregs versus activated effectors might determine 
the result. This hypothesis needs further investigation. 
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Figure 4.6. Islet graft histology and immunofluorescence for CD4+, CD8+, and Foxp3+ T cells. Sections from 
necroscopy islet grafts were stained with hematoxylin and eosin and the indicated immune cells (green) to reveal 
mononuclear infiltration in and around the islet grafts of NOD recipient mice (2 weeks after diagnosis) 6 weeks 
after therapy start (i.e. anti-CD3 alone (mono) or L. lactis-based combination therapy (combi)). DAPI was used as 
a nuclear stain (blue). At the time of normoglycemia at week 6 after transplantation, graft samples revealed well-
granulated islets with strong insulin staining (red) and massive infiltration of CD4+ or CD8+ T cells around the 
islets. Most notably, accepted grafts revealed the presence of Foxp3+ T cells around the islets. Photomicrographs 
(scale bar 75 µm) are representative of 10 sections per recipient. The patterns of cell infiltration were consistent 
across animals studied. Stains: hematoxylin and eosin (H&E, top row). 
 
mono combi
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4.3.5 L. lactis-based protection is associated with T-cell subset alterations 
To determine whether the therapeutic effect obtained by the treatment with anti-CD3 with or 
without L. lactis-based vaccine was related to a measurable alteration in the relative percentages 
of the main T-cell subsets, CD4+ and CD8+ T-cell populations were analyzed in spleen, 
pancreatic draining (PLN) and kidney draining lymph nodes (KLN) of cured and non-cured 
treated NOD islet recipient mice (2 weeks after diagnosis) 6 weeks after transplantation. 
Phenotypic characterization of T cells isolated from spleens and any of the lymph node 
compartments studied did not show significant differences in the percentages of CD4+ and 
CD8+ T cells (data not shown), and the CD4+/CD8+ ratios (Figure 4.7) remained comparable in 
all cured NOD islet recipient mice, regardless of therapy. However, the CD4+/CD8+ ratios were 
markedly higher in the spleen and PLN of cured treated NOD islet recipients compared to 
untreated controls and their non-cured treated counterparts. We did not observe differences in 
these T-cell frequencies related to diabetes duration at the time of islet implantation (data not 
shown). 
 
 
 
Figure 4.7. The ratio of CD4+ over CD8+ T cells in spleen, pancreatic and kidney draining lymph nodes of NOD 
islet recipients (2 weeks after diagnosis) 6 weeks after transplantation and treated with anti-CD3 alone (mono) or 
combined with L. lactis-based vaccine (combi). Each symbol represents an individual mouse, and horizontal bars 
indicate the median value. Crossed circles: untreated controls; white symbols: non-cured; black symbols: cured; 
triangles: monotherapy; squares: combination therapy. Statistical significance was calculated using Mann-Whitney 
t-test; *P < 0.05, **P < 0.01. PLN, pancreatic lymph node. KLN, kidney draining lymph node 
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Immune effector function at the target tissue can be controlled by various mechanisms 
coordinated by Tregs [409]. Unexpectedly, we observed lower CD4+Foxp3+ Treg frequencies 
in PLN and KLN of cured NOD islet recipients, irrespective of therapy, compared to untreated 
controls and non-cured treated counterparts (Figure 4.8). The percentages of CD4+Foxp3+ 
Tregs in different organs studied was not influenced by the time of diabetes diagnosis at the 
moment of islet implantation (data not shown). 
 
 
Figure 4.8. Flow cytometry of cells from spleen, pancreatic and kidney draining lymph nodes of NOD islet 
recipient mice (2 weeks after diagnosis; n=5 – 6), analyzing the frequency of Foxp3+CD4+ Treg cells in those 
tissues 6 weeks after transplantation and treated with anti-CD3 alone (mono) or combined with L. lactis-based 
vaccine (combi). Each symbol represents an individual mouse, and horizontal bars indicate the median value. 
Crossed circles: untreated controls; white symbols: non-cured; black symbols: cured; triangles: monotherapy; 
squares: combination therapy .PLN, pancreatic lymph node. KLN, kidney draining lymph node. Statistical 
significance was calculated using Mann-Whitney t-test; *P < 0.05, **P < 0.01. 
 
How exactly Tregs suppress the immune response in vivo is still debated. Whether in accepted 
islet grafts antigen-specific Tregs control the majority of antigen-experienced T cells at the site 
of inflammation/transplantation via direct contact, by modulating APCs and dampening the 
expression of the co-stimulatory molecules CD80 and CD80, or via other mechanisms is a 
matter of further studies. 
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4.4 DISCUSSION 
Contrasting with alloimmune responses, autoimmune disease recurrence is difficult to control 
with standard immunosuppression and therefore poses a challenging obstacle for a successful 
long-term islet cell transplantation outcome. Currently used T-cell-targeting strategies (i.e. 
ATG, alemtuzumab or anti-CD3) administered prior to the time of islet implantation are 
specifically designed to tackle alloimmunity and reduce the necessity for maintenance 
immunosuppression [399] but unexpectedly might predispose the graft to destruction by 
promoting the development and expansion of effector memory T cells [401]. An interesting 
approach that could diminish homeostatic expansion of autoreactive T cells is combining mild 
lymphodepletion with antigen-specific approaches that have the potential to reinstate 
immunological tolerance by the induction of islet antigen-specific Tregs and that obviate the 
need for maintenance immunosuppression [404–407].  
 
In this study, we used a combination therapy consisting of a short induction therapy of low 
doses of anti-CD3 mAbs combined with the intragastric delivery of a genetically-modified L. 
lactis-based vaccine producing human proinsulin along with pro-tolerogenic IL10 to reestablish 
tolerance to islet antigens in longstanding diabetic NOD islet recipients. This therapeutic 
approach has been shown by our group to reach approximately 60% of new-onset diabetes 
remission in NOD mice [74,201]. We postulate that the remaining 40% of the non-cured treated 
mice had possibly insufficient beta-cell mass at therapy entry to reach proper glycemic control, 
especially since mice with mild starting blood glucose concentrations (<350 mg/dl) had a 
superior (74%) diabetes reversal outcome [74]. Moreover, also the non-cured treated mice 
responded immunologically to the L. lactis-based combination therapy as demonstrated by the 
dramatic accumulation of Foxp3+ Tregs locally in the pancreas (Takiishi et al. personal 
communication). Although some T1D patients with disease duration of over 30 years still have 
detectable beta-cell function [410], it is clear that duration of diabetes leads to a progressive 
loss of beta-cell mass and function over many years [411]. As such, we transplanted, in the 
current study, 500 insulitis-free syngeneic NOD islets in either new-onset or longstanding 
diabetic NOD mice to immediately restore insulin secretion and promote normalization of 
hyperglycemia.  
 
Chatenoud et al. established in beta-cell autoimmunity that anti-CD3 mAb therapy can shift the 
balance of activated effector T cells and Tregs toward a more tolerant phenotype but only when 
  Chapter 4: Restoration of self-tolerance after islet transplantation 
 
68 
 
applied in the context of a primed immune system [408,412]. Based on these observations and 
the pharmacokinetic profile of anti-CD3, we designed a first therapeutic regimen starting day –
5 of islet implantation to specifically tackle the activated effector T-cell pool, which is a 
prerequisite for the generation of a therapeutic window allowing Tregs to induce and maintain 
graft tolerance. Although this early regimen with low-dose anti-CD3 combined or not with L. 
lactis-based antigen-specific therapy induced graft acceptance in around 20% of NOD islet 
recipients compared to 0% in untreated controls, most islet grafts were destroyed [221,413]. 
We speculate that since effector memory CD8+ T cells are eventually resistant to 
lymphodepletion [414,415], repopulate faster than their CD4+ counterparts in a lymphopenic 
environment [416], especially after an antigen recall [417], without homing to secondary 
lymphoid organs and contact with MHC class I molecules [418,419], islet implantation (i.e. 
antigenic stimulation) during the period of lymphopenia-induced homeostatic proliferation of 
remaining T cells seems not the best therapeutic option. Our data further support the theory that 
resistance to tolerance induction after homeostatic proliferation is most likely the result of the 
generation of antigen-experienced T cells. Importantly, others already demonstrated that 
reconstitution of memory T cells in the presence of an allograft accelerates graft rejection [416]. 
 
In a second therapeutic regimen in which therapy started at the time of islet implantation, the 
overall graft acceptance was around 34 and 56% in anti-CD3- and combination therapy-treated 
NOD islet recipients, respectively. Although antigen-experienced T cells can mount strong 
(auto)immune responses in the absence of secondary lymphoid organs [420], these unique 
properties are not shared by either naïve or memory-like T cells generated in the absence of an 
antigenic (re)encounter [418], implying that islet implantation (i.e. antigen stimulation) before 
lymphodepletion would not only limit the homeostatic proliferation of the antigen-experienced 
T-cell pool, but would preferentially trigger the expansion of Foxp3+ Tregs and promote long-
term tolerance induction. These hypotheses need further investigation.  
 
An import observation of our study is that not only the timing of islet implantation in relation 
to the T-cell-depletion strategy influences transplant outcome but also that diabetes duration 
before islet implantation impacts on the rate of success. Interestingly, the efficiency to prevent 
autoimmune diabetes recurrence clearly diminished in anti-CD3-treated mice with diabetes 
duration. In contrast, L. lactis-based combination therapy-treated mice were significantly better 
at avoiding disease recurrence and much less influenced by duration of diabetes. Here, we put 
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forward that the rate of normoglycemia restoration and the rate of graft acceptance in relation 
to the timing of diabetes diagnosis is in part related to the protection of residual endogenous 
islets in the pancreas as reflected by the insulin content of the native pancreas at different time 
points after diabetes diagnosis. Although we established in previous studies that our L. lactis-
based combination therapy does not stimulate beta-cell regeneration in the pancreas, it can 
preserve the functional beta-cell mass at therapy entry, which is directly related to a higher 
degree of diabetes reversal [74]. Likewise, some patients can maintain endogenous insulin 
secretion, as estimated from their C-peptide concentrations, for over 30 years after diagnosis 
[410], implying that C-peptide positive patients might have better islet transplant outcomes 
compared to T1D patients with established disease (i.e. C-peptide negative). 
 
Next, we suggest that the L. lactis-based combination therapy is superior in preventing 
autoimmune diabetes recurrence in NOD islet recipients compared to anti-CD3 monotherapy 
due to the delivery of an islet antigen (i.e. proinsulin) in a tolerogenic manner. We demonstrated 
in the past that this approach can reliable and safely reestablish long-term tolerance to 
autoantigens by generating antigen-specific CD4+Foxp3+CTLA4+ Tregs without elimination of 
the autoreactive T-cell compartment, which implies some resetting of the balance between 
autoreactive and tolerogenic cells [74]. Using a humanized mouse reconstituted with human 
hematopoietic stem cells, Waldron-Lynch et al. reported that anti-CD3 induced only a modest 
and transient T-cell depletion, but alternatively triggered the generation of a “gut-homing” 
CD4+CD25hiCCR6+Foxp3+ Treg population which produced IL10 on migration to the gut and 
subsequently returned to the circulation [421]. Nishio et al. further demonstrated that Treg 
expansion after anti-CD3 injection occurred not through conversion from Foxp3– conventional 
T cells, but via expansion of a monoclonal Treg population, normally selected and sustained at 
low frequency [224]. Interestingly, they also proposed that a minor cytokine storm elicited by 
anti-CD3 mAbs may actually be crucial contributing elements in the therapeutic effect, via 
resetting of the Treg niches. We suggest that when combined with islet antigen delivered via 
the tolerogenic route, anti-CD3 mAbs may encourage, rather than a general Treg expansion, 
specific modifications in the homeostatic control of their islet antigen-specific repertoire or a 
phenotypic redistribution. The L. lactis-based combination therapy would preferentially 
generate and expand islet antigen-specific Tregs which are known to be more suitable for 
controlling autoimmunity in situ, especially when the islet antigen is still present, than 
polyclonal Tregs [422]. In our study, we found that NOD islet recipients treated with anti-CD3 
alone or combined with the L. lactis-based vaccine had Foxp3+ Tregs present in the lymph 
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nodes draining the islet implantation site (i.e. kidney) but this percentage was not different 
between mono- and combination therapy and independent of diabetes duration. In addition, we 
observed that non-cured treated counterparts had even higher Treg frequencies in their kidney 
and pancreas-draining lymph nodes compared to lymph nodes from NOD islet recipients with 
accepted grafts. We propose that Tregs may accumulate at the implantation site, where they 
suppress the effector function of islet antigen-specific T cells. Much more insights are needed 
on whether the intragraft Tregs are indeed enriched with islet antigen-specific Tregs and how 
these Tregs can control the diverse repertoire of antigen-experienced T cells present in the islets 
[423]. Tregs can function through numerous mechanisms at the site of antigen stimulation; both 
in draining lymph nodes and at the site of inflammation/transplantation, to create a tolerogenic 
milieu that promotes bystander suppression and infectious tolerance. Also, the kinetics of 
peripheral islet antigen-specific Treg memory cells into tissues (other than the lymphoid tissue) 
remain unknown. 
 
In summary, a mild lymphodepletion with low-dose anti-CD3 mAbs in combination with the 
gut delivery of proinsulin along with pro-tolerogenic IL10 by genetically-modified L. lactis can 
by-pass autoimmune diabetes recurrence in 56% of syngeneic islets transplanted in 
longstanding diabetic NOD mice. Islet transplantation outcome will surely depend on the time 
of islet implantation in relation to T-cell-targeting strategy and on the time of islet implantation 
after diabetes diagnosis. Integration of these antigen-specific technologies to enhance 
engraftment and combat graft destruction may help to advance the therapeutic efficacy and 
availability of islet cell transplantation in selected patient populations. 
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IMPROVEMENT OF BETA-CELL ENGRAFTMENT
3
 
                                                 
3based on João Paulo Monteiro Carvalho Mori Cunha, Gunter Leuckx, Peter Sterkendries, Hannelie Korf, Gabriela 
Bomfim-Ferreira, Lutgart Overbergh, Bart Vaes, Harry Heimberg, Conny Gysemans, Chantal Mathieu. Human 
multipotent adult progenitor cells enhance islet function and revascularization when co-transplanted as a composite 
pellet in a mouse model of diabetes. Diabetologia 2017, 60(1), 134-142 
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5.1 INTRODUCTION 
To date, insulin therapy is considered the gold standard for the treatment of T1D. Nevertheless, 
limitations persist, such as frequent episodes of hypoglycemia, and chronic micro- and 
macrovascular complications [5,8]. Islet cell transplantation offers an alternative treatment for 
T1D patients, specifically for those with hypoglycemic unawareness following insulin 
administration. Despite the improved outcome of islet transplantation over the last few years, 
drawbacks remain, such as a limited supply of cadaveric donors, the necessity of several donors 
for a single transplantation, and (immediate) graft failure through metabolic pressure, continued 
autoimmunity, alloimmunity, high concentrations of immunosuppressive drugs, and oxidative 
stress caused by hypoxia or due to cytokine exposure [424]. Rapid revascularization of the islets 
seems crucial to avoid these last two complications. Several studies aiming to increase 
engraftment with cell therapy are currently ongoing (www.clinicaltrials.gov; NCT00646724, 
NCT02384018). 
 
MSC (30-35 µm in diameter), the major stem cells used for cell therapy, are self-renewing cells 
that can be isolated from the bone marrow but possibly also from many if not all tissues and 
have shown for over 10 years benefits in the treatment of several clinical diseases, mainly tissue 
injury and immune disorders [425–427]. When co-transplanted with islets, MSC improves islet 
cell transplantation outcome in preclinical animal models through immunomodulation, 
increasing islet revascularization and/or preserving islet morphology [345,346,355,428]. In 
spite of the progress in the understanding of MSC biology, there is little knowledge on the 
nature of their local microenvironment (probably hypoxic) and their functions in vivo. 
Moreover, long population doubling time, early senescence, and DNA damage during in vitro 
expansion as well as poor engraftment after transplantation are considered to be among the key 
disadvantages of MSC therapy [429]. Furthermore, with long-term culture expansion, MSC can 
become karyotypically abnormal which may pose a risk of tumor formation. 
 
MAPC® (15-20 µm in diameter) are adult stem cells isolated from postnatal bone marrow, 
muscle or brain from rodent and human tissue [356,357]. These non-hematopoietic, non-
endothelial stem cells most probably use similar immunosuppressive and angiogenic 
mechanisms as MSC although displaying unique features (e.g. secretome, transcriptome, and 
miRNA profiles) distinctive from most adult stem cells [364,430–432]. Interestingly, MAPC 
have been shown to promote tissue repair and healing and induce neo-angiogenesis, possibly 
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by delivering angiogenic growth factors that activate/recruit endogenous vascular cells and that 
seem to be specifically tailored to the immediate needs of the injured tissue [360–363]. In vivo, 
these cells are short-lived as they experience only a minimally prolonged residence time. 
Moreover, in contrast to other cell types, MAPC can be expanded long-term (for >80 population 
doublings) without genetic instability, and administered without tissue matching, making them 
into an optimal stem cell product for routine clinical use (MultiStem®, Athersys Inc., 
Cleveland).  
 
5.2 EXPERIMENTAL DESIGN 
The therapeutic potential of co-transplantation of undifferentiated human MAPC with mouse 
islets as separate or composite pellets was validated in a syngeneic marginal mass islet cell 
transplantation model. For this, alloxan-induced diabetic C57BL/6 mice were transplanted with 
syngeneic islets either alone (control) or co-transplanted as separate pellets (SEP) with human 
MAPC or as composite pellets (MIX) with human MAPC (Figure 5.1). 
 
 
Figure 5.1. Experimental setup. C57BL/6 mice were rendered diabetic by iv injection of alloxan (90 mg/kg BW). 
After 2 days, diabetic mice were transplanted with 150 C57BL/6 islets under left kidney capsule either alone 
(control) or together as separate pellets with human MAPC (2.5 × 105) or as composite pellets with human MAPC 
(2.5 × 105). Weight and glycemia were measured three times weekly. IPGTTs were performed two days before 
sacrifice. Animals were killed for graft histology and gene expression analyses 2 and 5 weeks post-transplantation.  
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5.3 RESULTS 
5.3.1 Human MAPC secrete angiogenic growth factors and have neo-angiogenic potential 
in the in vivo CAM 
Human MAPC presented a low expression of HLA-ABC (<25%) and lacked expression of 
HLA-DR, CD40, CD86, CD3, Flk1/VEGFR2/KDR, CD31/PECAM-1, and CD34 (< 1%), 
which are typical cell surface markers for MHC class II and co-stimulation molecules, T cells 
and endothelial cells, respectively (Figure 5.2). Human MAPC were positive for CD44 and 
CD105 (>95%)[365]. Their surface marker signature defines a unique phenotype that 
distinguishes them from any other known class of stem cells [365]. 
 
Figure 5.2. Characterization of human MAPC. Cell surface marker expression of human bone marrow-derived 
MAPC. Flow cytometry histograms show the expression levels (shaded dark gray peaks) of selected markers 
associated with the characterization of human MAPC [CD44 and CD105] compared with negative isotype controls 
(shaded light gray peaks).  
 
The culture supernatant of human MAPC was analyzed with a human biomarker 40-Plex kit 
containing a proinflammatory panel, cytokine panel, chemokine panel, angiogenesis panel and 
vascular inflammation panel (Figure 5.3A). The cells produced numerous angiogenic growth 
factors, including VEGF (VEGF-A, -C and -D), PlGF, sFlt-1, bFGF, and IL8. On the other 
hand, the cells had negligible secretion of various cytokines (i.e. IFN-γ, IL1α, IL1β, IL2, IL4, 
IL5, IL6, IL7, IL10, IL12p70, IL12/IL23p40, IL13, IL15, IL16, IL17A, TNF-α, and TNF-β), 
and chemokines (Eotaxin, Eotaxin-3, IP-10, MCP-1, MCP-4, MDC, MIP-1α, MIP-1β, and 
TARC)(data not shown). 
  Chapter 5: Improvement of beta-cell engraftment 
 
76 
 
The neo-angiogenic potential of human MAPC was tested using the CAM angiogenesis model. 
Inoculation with 5 µg recombinant human VEGF markedly increased the number of blood 
vessels directed toward the implant (Figure 5.3B). Human MAPC (2.5 × 105) significantly 
increased vessel formation by 2.5- and 4.6-fold compared to control implants containing either 
150 mouse C57BL/6 or 50 µg BSA respectively (Figure 5.3B). 
 
Figure 5.3. Angiogenic potential of human MAPC. (A) Culture medium of human MAPC was analyzed with 
human biomarker 40-Plex kit containing a proinflammatory panel, cytokine panel, chemokine panel, angiogenesis 
panel and vascular inflammation panel (protein secretion in pg/mL); (B) Pro-angiogenic properties of 2.5 × 105 
human MAPC with or without 150 C57BL/6 mouse islets in a chorioallantoic membrane (CAM) assay, with 150 
C57BL/6 mouse islets alone and BSA as negative control and VEGF-A as positive control (mean ± SEM, n=3-9 
per group). **P < 0.01; ***P < 0.001.  
 
5.3.2 Co-transplantation of islet-human MAPC as a composite pellet improves the outcome 
of marginal mass islet cell transplantation 
First, we titrated the number of pancreatic islets transplanted to determine ‘a marginal islet 
mass’ that would be just at the edge of achieving normoglycemia in around 50% of recipients. 
Transplantation of 50 syngeneic C57BL/6 islets did not reverse hyperglycemia (0 out of 7 
mice), whereas 100% (4 out of 4 mice) achieved normoglycemia when 300 islets were 
transplanted under the kidney capsule. We assessed that the marginal islet number was 
approximately 150 islets (25 out of 45 mice, 56% achieving normal blood glucose 
concentrations 5 weeks post-transplantation). This number of islets was selected for further 
experiments.  
0
1 0
2 0
3 0
4 0
5 0
B
lo
o
d
 v
e
s
s
e
ls
 p
e
r 
im
p
la
n
t
h
M
A
P
C
h
M
A
P
C
+
is
le
ts
is
le
ts
V
E
G
F
B
S
A
* *
* * *
S
A
A
s
IC
A
M
-
1
s
V
C
A
M
-
1
C
R
P
V
E
G
F
-
A
P
IG
F
s
F
L
t-
1
b
F
G
F
V
E
G
F
-
C
V
E
G
F
-
D
IL
8
/C
X
C
L
8
0
2 0
4 0
6 0
2 0 0
4 0 0
6 0 0
8 0 0
1 ,0 0 0
2 ,0 0 0
4 ,0 0 0
6 ,0 0 0
P
ro
te
in
 c
o
n
c
e
n
tr
a
ti
o
n
 (
p
g
/m
l)
v a s c u la r  in fla m m a tio n a n g io g e n e s is
A B hMAPC
BSA
VEGF
  Chapter 5: Improvement of beta-cell engraftment 
 
77 
 
Next, we investigated the outcome of the co-transplanted marginal islet mass with 2.5 × 105 
human MAPC as separate or composite pellets and monitored blood glucose levels of 
transplanted animals up to 5 weeks. Co-transplantation of pancreatic islets with human MAPC 
as separate pellets (SEP) slightly improved the average blood glucose concentrations compared 
to mice transplanted with islets alone. Interestingly, mice receiving islet-human MAPC 
composites (MIX) had better glycemic control at all measured time points from 2 weeks 
onwards (Figure 5.4A). Three weeks after transplantation, 81% of the mice transplanted with 
islet-human MAPC composites (13 out of 16 mice in the MIX group) were normoglycemic 
compared to 50% of the mice transplanted with islet-human MAPC as separate pellets (13 out 
of 26 mice in the SEP group; P < 0.05) and 47% in the mice transplanted with islets alone (21 
out of 45 mice in the control group; P < 0.05)(Figure 5.4B). By the end of the observation period 
(week 5 post-transplantation), even a greater proportion of mice co-transplanted with islet-
human MAPC reversed diabetes compared to mice transplanted with islets alone (94% in the 
MIX group, p<0.01 and 85% in the SEP group, P < 0.001 versus 56% in the control group).  
Figure 5.4. In vivo function of a marginal islet mass co-transplanted with human MAPC. (A) Blood glucose 
measurements of alloxan-induced diabetic C57BL/6 mice transplanted with 150 islets alone (control; white bars) 
or 150 islets co-transplanted as separate (SEP, dark gray bars) or composite pellets (MIX, light gray bars) with 2.5 
× 105 human MAPC. *P < 0.05, **P < 0.01, ***P < 0.001 versus islet-alone group (control), (B) Percentage of 
cured (back bars) and non-cured (gray bars) mice after islet cell transplantation. 
 
After nephrectomy, the blood glucose concentrations of normoglycemic islet recipients rapidly 
progressed to severe hyperglycemia, indicating that the improvement in metabolic glucose 
control was resulting from the transplanted syngeneic islets and not from the regeneration of 
remnant islets in the alloxan-treated pancreas of the islet recipients (Figure 5.5A). Moreover, 
there was no significant difference in body weight between transplant recipients from different 
  Chapter 5: Improvement of beta-cell engraftment 
 
78 
 
experimental groups on day 0 (22.8 ± 0.27, 23.5 ± 0.2 and 22.9 ± 0.21 g for the control, SEP, 
and MIX groups, respectively, n=40-52) or at week 5 post-transplantation (25.6 ± 0.33, 26.2 ± 
0.32 and 25.4 ± 0.27 g, for the control, SEP, and MIX groups, respectively, n=40-52)(Figure 
5.5B).  
 
Figure 5.5. Non-fasting glycemia and body weight of transplant recipients. (A) Blood glucose concentrations were 
monitored in alloxan-induced diabetic C57BL/6 mice transplanted with 150 syngeneic islets either alone (white 
circles) or co-transplanted with 2.5 × 105 human MAPC (as separate (crossed circles) or composite (gray circles) 
pellets) for over 5 weeks. Recovery nephrectomies performed in randomly selected animals of each group at 5 
weeks post-transplant resulted in 100% return to hyperglycemia. (B) Body weight changes did not significantly 
differ between the various groups throughout the study period. Each value represents the mean ± SEM.  
 
Serum mouse insulin and C-peptide levels were measured 2 and 5 weeks after transplantation, 
as an index of islet graft function. At week 2 post-transplantation, insulin and C-peptide 
concentrations were not significantly different between the various experimental groups (Figure 
5.6A). However, at week 5 post-transplantation, C-peptide values were significantly better in 
mice co-transplanted with islet-human MAPC as separate pellets (304 ± 80 pmol/l in the SEP 
group; n=10, P < 0.01) as well as composite pellets (282 ± 77 pmol/l in the MIX group; n=10, 
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P = 0.05) compared to values from the islet-alone mice (232 ± 52 pmol/l in the control group; 
n=10) (Figure 5.6B).  
 
Figure 5.6. Serum insulin and C-peptide concentrations 2 (A) and 5 weeks (B) post-transplantation. Mice were 
transplanted with 150 islets alone (white bars) or with 150 islets together with human MAPC as separate pellets 
(SEP, dark gray bars) or as a composite pellet (MIX, light gray bars). **P < 0.01 versus islet-alone group (control). 
 
To investigate the insulin secretory capacity of the islet transplant, a series of intraperitoneal 
glucose tolerance tests (IP-GTT) were performed week 2 and 5 post-transplantation. At week 2 
post-transplantation, there were no significant differences in glucose clearance among the 
studied groups. On the other hand, at week 5 post-transplantation, mice co-transplanted with 
islet-human MAPC composites (MIX) cleared glucose more efficiently than mice transplanted 
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with islets and human MAPC as separate pellets (SEP) or with islets alone (control)(Figure 
5.7A-B). To further support the observations of the IP-GTT, area under the curve (AUC) was 
calculated and found to be significantly different between the group transplanted with islet-
human MAPC composites (MIX) compared to the group transplanted with islets and human 
MAPC as separate pellets (SEP) (P < 0.01) or transplanted with islets alone (control)(P < 0.01). 
(Figure 5.7A-B). 
 
Figure 5.7. In vivo function of a marginal islet mass co-transplanted with human MAPC. (A, B) Area under the 
curve (AUC) and blood glucose measurements of IPGTTs in all mice 2 (A) and 5 (B) weeks after transplantation, 
**P < 0.01 versus islet-alone group (control). 
 
5.3.3 Increased beta- and alpha-cell volume and blood vessel formation in mice 
transplanted with islet-human MAPC composites 
Grafts from the co-transplant and islet-alone groups were evaluated for their gene profile, 
cytoarchitecture and revascularization process. Insulin and glucagon mRNA expression levels 
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were significantly higher in mice co-transplanted with islet-human MAPC composites (MIX) 
compared to those of the islet-alone group (control) 2 weeks after transplantation. There was 
no difference in somatostatin mRNA expression levels at this time point. At week 5 post-
transplantation, the intragraft mRNA levels of the studied endocrine hormones were 
comparable in all groups (Figure 5.8A-B). 
 
Figure 5.8. Gene expression in islets co-transplanted with human MAPC 2 and 5 weeks post-transplantation. Box 
and whiskers plots of mRNA levels of mouse insulin, glucagon, and somatostatin in isolated islet grafts. Data are 
expressed as a relative value compared to house-keeping genes. Statistical analysis was calculated using Mann-
Whitney t-tests. *P < 0.05.  
 
These measures were corroborated by histology of the grafts, showing significantly higher 
insulin-, glucagon-, and somatostatin-positive areas in the grafts of mice transplanted with islet-
human MAPC composites (MIX) 2 weeks after transplantation, compared to mice transplanted 
with islets only (control) (Figure 5.9A-B). 
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Figure 5.9. Morphology and composition of islets co-transplanted with human MAPC 2 and 5 weeks post-
transplantation. (A) Box and whiskers plots of volumes of beta-, alpha- and delta-cells of grafts derived from mice 
transplanted with a marginal islet mass alone or combined with human MAPC as a separate or composite pellet. 
Statistical analysis was calculated using Mann-Whitney t-tests. *P < 0.05; **P < 0.01. (B) Distribution of mouse 
insulin- (white), glucagon- (red), and somatostatin (green)-positive cells in islet grafts composed of islet-human 
MAPC as separate (SEP) or composite (MIX) pellets or of islets alone (control) at 2 weeks post-transplantation. 
Stitched composite images are representative of sections from 4-8 different animals. Scale bar is 100 μm. Higher 
magnification of the boxed area in control demonstrates a compact graft with a normal distribution of insulin, 
glucagon and somatostatin positivity. Higher magnification of the boxed area in SEP and MIX group shows 
spread-out grafts with high insulin and glucagon positivity.  
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Blood vessel formation was measured by endomucin expression, a marker for vascular 
endothelial cells. At week 2 post-transplantation, graft vessel density and area as well as ratio 
of the vessel area over insulin-positive area did not differ between the studied groups. At week 
5 post-transplantation, enhanced graft revascularization was observed in mice co-transplanted 
with islets-human MAPC composites (MIX) compared to mice transplanted with islet-human 
MAPC as separate pellets (SEP) or with islets alone (control). In the MIX grafts, 1256 ± 203 
vessels per mm2 were detected, compared to 702 ± 106 per mm2 in the SEP grafts and 515 ± 
52 per mm2 in the islet-alone grafts (both P < 0.05; Figure 5.10A-B). Another index of neo-
angiogenesis, graft vessel area, was significantly higher in the MIX grafts (4.85 ± 1.32%, n=5), 
than in the SEP grafts (2.04 ± 0.57%, n=5) or the grafts of islets only (1.26 ± 0.25%; n=4, P < 
0.05, Figure 5.10B). Additionally, mice transplanted with the MIX grafts had a higher ratio of 
vessel per insulin-positive area than the SEP grafts and islet-alone grafts (0.079 ± 0.027 versus 
0.019 ± 0.006 and 0.014 ± 0.003 vessels per islet, both P < 0.01)(Figure 5.10A-B).  
Figure 5.10. Co-transplantation of islets with human MAPC as composites promotes graft revascularization in a 
marginal islet mass diabetic mouse model. (A) Representative sections of 5-week grafts consisting of mouse islets 
transplanted alone or with human MAPC as separate (SEP) or composite (MIX) pellet. Images are representative 
of insulin and endomucin (vessel) staining for 3-4 animals in each transplant group. Scale bar is 100 μm. (B) 
Vessel morphologic parameters assessment was determined as described in material and methods section. Data 
are means ± SEM. Statistical analysis was calculated using Mann-Whitney t-tests. *P < 0.05, **P < 0.01. 
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Collectively, grafts composed of islets mixed with human MAPC retrieved 5 weeks after 
transplantation contained high numbers of endomucin-positive endothelial cells (Figure 4.10A) 
and only a few α-SMA-positive cells (Figure 5.11A), indicative of the presence of new 
capillary-like structures. Moreover, PCR analyses demonstrated that both mouse 
CD31/PECAM-1 in addition to α-SMA mRNA were more abundantly present in the MIX grafts 
compared to the islet-alone group (Figure 5.11B), while expression of the basement membrane 
marker Col4a1 was not different among the experimental groups (data not shown). 
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Figure 5.11. Human MAPC influence islet graft revascularization under kidney capsule 5 weeks post-
transplantation. (A) Distribution of mouse insulin- (green), endomucin- (red), and α-SMA (blue)-positive cells in 
islet grafts composed of islet-human MAPC as separate (SEP) or composite (MIX) pellets or of islets alone 
(control) at 5 weeks post-transplantation. Stitched composite images are representative of sections from 4-8 
different animals. Scale bar is 500 μm. Higher magnification of the boxed area in the MIX group shows a high 
number of endomucin-positive endothelial cells with very few α-SMA-positive cells that encircle a well-defined 
lumen with fenestrations towards the adjacent endocrine cells, indicative of a new capillary-like network. This 
aspect may support the advanced functionality of the graft. (B) Box and whiskers plots of mRNA levels of mouse 
CD31/PECAM-1 and α-SMA in isolated islet grafts. Data are expressed as a relative value compared to house-
keeping genes. Statistical analysis was calculated using Mann-Whitney t-tests. *P < 0.05. 
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5.4 DISCUSSION 
Several hurdles still prevent the progression of clinical islet transplantation, including early 
graft failure and the loss of transplanted islet mass due to nonimmunological reasons [433]. In 
the first days following transplantation, islets lack an adequate vascular network, leading to 
severe hypoxia and cell death. It is believed that this is one of the major causes of the poor 
performance of islet grafts longterm. Therefore, there is a need for methods to improve the early 
survival, function and engraftment of transplanted islets. A variety of (stem) cell populations 
(i.e. endothelial progenitor cells, MSC) have been described to enhance transplanted beta cell 
survival and function after co-transplantation, however there are still hurdles to their wide 
application in the clinic, such as inconsistent stem cell potency, poor cell engraftment and 
survival, and age/disease-related host tissue impairment [434]. 
 
A novel class of progenitor cells is the MAPC® which can be derived from the postnatal bone 
marrow stromal compartment but also from muscle and brain of several species, including 
rodents and humans [357]. These cells have demonstrated extensive in vitro expansion capacity, 
durable cytogenetic stability, and higher plasticity compared to MSC [435]. MAPC are also 
non-immunogenic cells with a strong immunomodulatory profile [364–366,436–439], 
permitting safe non-HLA-matched allo- and even xenogeneic use without the need for 
immunosuppression [440,441]. Interestingly, MAPC seemed to exhibit an unusual capacity to 
evade the immune system and can regulate homeostatic T-cell proliferation, prevent the 
expansion of Th1, Th17, and Th22 effector T cells, and block the generation of pathogenic 
allogeneic responses [366]. Moreover, MAPC has been described to secrete angiogenic growth 
factors and to improve vascular remodeling in different ischemic models, such as those for 
cardiac infarction and severe limb ischemia [362,441]. Based on these phenotypic and 
functional characteristics, we wanted to study the localized effect of human MAPC on islet 
graft function in a murine syngeneic marginal mass transplant model. 
 
Here we show for the first time that human MAPC co-transplanted as composite pellets with 
mouse islets can improve islet graft function as measured by the initial glycemic control, 
diabetes reversal rate, glucose tolerance, and serum C-peptide concentration compared with 
transplantation of islets alone. Moreover, we found that grafts composed of islet-human MAPC 
composites had an improved revascularization process. The human MAPC actively participated 
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in the revascularization process mainly by producing angiogenic growth factors, soluble 
adhesion molecules and IL8.  
 
Several studies have shown that MAPC from both allo- and xenogenic sources exert positive 
effects in ischemia models, mainly through the secretion of trophic factors such as VEGF-A, 
platelet-derived growth factor (PDGF) and insulin-like growth factor-1 (IGF-1) [441,442]. Our 
present data corroborated the angiogenic potency of human MAPC as supernatants of cultured 
cells were shown to contain high concentrations of vascular inflammation and angiogenic 
factors such as VEGF-A, PlGF, bFGF, all major regulators of islet vascularization. The neo-
angiogenic potential of human MAPC was further validated in vivo in a chicken CAM assay, 
where implanted human MAPC formed new blood vessels at a rate comparable to recombinant 
VEGF-A. VEGF-A is described to be one of the major regulators of islet vascularization, 
innervation and function, as beta cell-specific deletion of VEGF-A leads to diminished and 
abnormal islet vascularity, impaired postnatal nerve fiber ingrowth, and a pre-diabetic 
phenotype [443–445]. Moreover, VEGF-A seems to be required for revascularization of 
transplanted islets. Based on these data, several investigators have tried to enhance VEGF 
production locally in the pancreatic islets although not continuously as this might trigger 
vascular tumor formation [446–448]. Just now, it has been reported that islets co-transplanted 
with human embryonic stem cell-derived MSC that conditionally overexpress VEGF allow a 
50% reduction in the islet mass required to reverse diabetes in mice. These cells significantly 
improved islet metabolic function and revascularization [428]. 
 
Islet engraftment is a slow process, and while vascular sprouting, angiogenesis, and 
revascularization occur within 1-2 weeks after transplantation, the maturation of the blood 
vessels is likely to take several weeks to even months. Although VEGF can boost the process 
of islet revascularization, this protein is also critical to maintain the intraislet endothelial cell 
pool [444]. We found a significant improvement in the development of a new islet capillary 
network in mice where islets were co-transplanted with human MAPC. Indeed, higher numbers 
of capillary-like structures with a lining of endothelial cells (detected with mouse-specific 
endomucin antibody), were found on the periphery and in the intra-islet space of the islet-human 
MAPC composites at week 5 post-transplantation, suggesting that host-derived vessels are 
directly feeding transplanted islets and that close proximity and even direct contact between the 
transplanted pancreatic islets and human MAPC is of critical importance for the improved 
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glucose control, diabetes reversal rate and increased revascularization. The absence of human 
CD31/PECAM-1 mRNA expression in the islet grafts further supports the idea that human 
MAPC do not incorporate into new capillaries but possibly secrete growth factors to initiate 
angiogenesis and to support functional tissue survival (data not shown). These observations are 
in full agreement with previous observations that the major role of human MAPC is to provide 
angiogenic growth factors in the first days after implantation, after which they are cleared 
rapidly from the body, without leading to immune activation [360,441]. 
 
The present data encouraged the use of human MAPC in islet cell transplantation protocols as 
our results demonstrate the improvement of islet graft morphology and function by 
transplantation of islets-human MAPC composites, possibly via the promotion of graft 
revascularization mediated by human MAPC. 
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Type 1 diabetes (T1D) is a debilitating disease characterized by a chronic incapability to 
normalize hyperglycemia. Transplanting cadaveric pancreases or isolated islets can restore 
glucose homeostasis during the first year and return hypoglycemia awareness, thus alleviating 
severe hypoglycemia. Despite the improved outcome of islet transplantation over the last few 
years, it is clear that the organ demand outnumbers the supply. Therefore, all islet transplant 
programs need to be highly selective in which patients to admit. Immunosuppression is also 
challenging [424]. Research into more focused, less harmful immunosuppressive regimens is 
urgently needed to tackle allorejection, recurrence of autoimmune diabetes and immediate graft 
failure. 
 
Several studies described that anti-CD3 mAbs can induce long-term tolerance in allografts and 
in autoimmune settings [222,223]. Unfortunately, lymphodepletion regimens like induction 
therapy with anti-CD3 mAbs have been shown to be accompanied by a homeostatic expansion 
of islet-specific autoreactive T cells with effector memory phenotype [401] and seem to 
predispose the graft to destruction. Therefore, therapeutic approaches that could block both 
allo- and autoimmunity while circumventing homeostatic expansion of autoreactive T cells 
would be the medicinal Holy Grail. Ongoing efforts are addressing this need by combining mild 
lymphodepletion with antigen-specific approaches that have the potential to reinstate 
immunological tolerance by the induction of islet antigen-specific Tregs and that could obviate 
the need for maintenance immunosuppression [404–407].  
In chapter 4, we used a combination therapy consisting of a short induction therapy of low 
doses of anti-CD3 mAbs combined with the intragastric delivery of a genetically-modified L. 
lactis-based vaccine producing human proinsulin along with pro-tolerogenic IL10 to reestablish 
tolerance to islet antigens in longstanding diabetic NOD islet recipients. We demonstrated that 
the success of the therapy depended not only on the time of islet implantation in relation to 
diabetes duration but also to T-cell-targeting strategy as already demonstrated by others 
[222,223]. We speculate that islet implantation before, instead of, after lymphodepletion would 
not only limit the homeostatic proliferation of the antigen-experienced T-cell pool but would 
also allow the expansion of Foxp3+ Tregs and promote long-term tolerance induction. These 
hypotheses need further investigation. Le Campion et al. demonstrated that IL2 and IL7 control 
the homeostatic balance between the regulatory and conventional CD4+ T-cell compartments 
during peripheral T-cell reconstitution [449]. In addition, IL15 could play a role together with 
IL7 in the generation of memory T cells [283,288]. Thus, we believe that analyses of these 
cytokines in the serum at differents time points after islet implantation would help to understand 
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the homeostatic proliferation in our work. Moreover, FACS analyses on peripheral blood can 
be used to establish the balance between the different T-cell populations.  
We also found that NOD islet recipients treated with anti-CD3 alone or combined with the L. 
lactis-based antigen-specific vaccine had lower frequencies of Foxp3+ Tregs in the lymph nodes 
draining the islet implantation site (i.e. kidney) compared to untreated controls. This percentage 
was not different between mono- and combination therapy and independent of diabetes duration. 
The fact that the frequency of Foxp3+ Tregs did not increase after therapy in draining lymph 
nodes does not exclude that Tregs mediated syngeneic graft tolerance in NOD islet recipient 
mice. More insights are needed on whether intragraft Tregs are enriched with islet antigen-
specific Tregs and how these islet antigen-specific Tregs can control the diverse repertoire of 
antigen-experienced T cells present in the islets [423]. Also, the kinetics of peripheral islet 
antigen-specific Treg memory cells into tissues (other than the lymphoid tissue) remain 
unknown. The use of specific class I and II HLA tetramers with peptides from diabetes-
associated antigens could offer a better understanding of these processes [111,450]. Analyses 
on peripheral blood with such tetramers at different time points after islet implantation would 
allow insights into the kinetics of autoantigen-specific T cells. In addition, it would aid our 
understanding of the beta-cell protective processes and would establish whether graft and 
endogenous islets are enriched with autoantigen-specific Tregs as we hypothesize. 
The L. lactis bacteria can be genetically modified to secrete virtually any protein or peptides 
[451]. We propose that the use of L. lactis bacteria secreting human proinsulin along with other 
immunomodulatory cytokines like TGF-β instead of IL10 could expand the islet-resident 
antigen-specific Foxp3+ Treg pool and consequently suppress ongoing T1D after islet 
transplantation. Perhaps, future work could test this concept. 
Finally, we describe specific events in the autoimmune responses after islet implantation and 
lymphodepletion which represent therapeutic opportunities to restore long-term tolerance. 
More work is needed to fully understand the process of reestablishing tolerance in our model. 
We also need to further investigate how diabetes duration interferes with the efficacy of the 
treatment. These insights might be implemented in the clinic and could improve islet transplant 
outcomes in T1D patients after islet transplantation. 
 
Significant improvements in islet purification techniques and original immunomodulatory 
agents have renewed interest in islet transplantation. However, the field is still confronted by a 
limited supply of islet cells, insufficient engraftment, immediate graft failure and loss of 
  Chapter 6: General conclusions and perspectives 
 
94 
 
transplanted islet mass due to nonimmunological reasons [433]. In the first days following 
implantation, islets lack an adequate vascular network, leading to severe hypoxia and cell death. 
Another hypoxia-associated threat is that a microenvironment of hypoxia triggers the innate 
immune system, resulting in the release of inflammatory cytokines. It is believed that this is 
one of the major causes of the poor performance of islet grafts longterm. In chapter 5, we co-
transplanted MAPC® with mouse islets to improve engraftment. In addition to the beneficial 
role of stem cells in the immunomodulatory response and in encouraging beta-cell regeneration 
following transplantation, they may also play an important role in promoting islet 
revascularization. We showed for the first time that human MAPC co-transplanted as composite 
pellets with a marginal mass of syngeneic islets under the kidney capsule of alloxan-induced 
diabetic mice can improve islet graft function as compared with transplantation of islets alone. 
Moreover, we found that grafts composed of islet-human MAPC composites had an improved 
revascularization process. We found a significant improvement in the development of a new 
islet capillary network in mice where islets were co-transplanted with human MAPC. These 
observations are in full agreement with previous observations that the major role of human 
MAPC is to provide angiogenic growth factors in the first days after implantation, after which 
they are cleared rapidly from the body, without leading to immune activation [360,441]. 
 
Several studies are ongoing in the (stem) cell therapy field. The potential of progenitor cells to 
be used as an infinite and renewable source of insulin-producing beta cells to solve the problem 
of limited donors and support engraftment in human islets transplantation has led to stimulating 
avenues of application. In our work, we found that the physical contact of MAPC with islets 
impacted positively on the engraftment and function of the graft. Thus, devices or new 
technologies that could maintain the close interaction between the implanted islets and MAPC 
would be an interesting approach. Islets can be transplanted together with extracellular matrix 
(ECM) molecules under the skin or in the peritoneal cavity in 3-dimensional (3D) structures. 
Moreover, the new technologies with 3D printers which can make scaffolds for tissue 
engineering and 3D cell culture systems may hopefully advance the islet transplantation field 
[452]. These biopolymeric scaffolds provide a 3D structure for the islets, mimic the pancreatic 
microenvironment and keep the close interaction needed when MAPC are co-transplanted with 
islets. Furthermore, islets engraft more efficiently in 3D than in 2D structures, and the scaffold 
may increase viability by encouraging cell adherence and nutrient diffusion [453] which could 
further potentiate the favorable MAPC effects. 
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In addition, scaffolding may also allow for local administration of immunomodulatory drugs to 
suppress the specific allo- and autoimmune responses against the islets. Here, the exploitation 
of the immunomodulatory properties of MAPC can be used in allogeneic transplantation 
settings decreasing the use of immunosuppressive drugs that often have unwanted effects. 
Interestingly, MAPC seems to exhibit an unusual capacity to evade the immune system and can 
regulate homeostatic T-cell proliferation, prevent the expansion of Th1, Th17, and Th22 
effector T cells, and block the generation of pathogenic alloimmune responses [366]. Future 
experiments need to be performed using allogeneic islets in the autoimmune diabetes setting to 
assess the full immunomodulatory potential of MAPC. As MAPC can regulate homeostatic T-
cell proliferation, they could be exploited as maintenance therapy in islet transplantation after 
lymphodepletion regimens. 
 
As a general conclusion, the data presented in this PhD thesis explored promising therapeutic 
approaches to improve islet transplant outcomes. Our work indicates that these approaches 
should act on different levels to overcome the many hurdles of beta-cell replacement in the 
modality of islet cell transplantation (Figure 6.1). We showed that genetically-modified L. 
lactis-based antigen-specific vaccines combined with a short course of low doses of anti-CD3 
mAbs can avoid autoimmune diabetes recurrence depending on the time of islet implantation 
in relation to T-cell-targeting strategy and on the time of islet implantation after diabetes 
diagnosis. We also showed that the use of human MAPC in islet cell transplantation can 
improve islet graft morphology and function by transplantation of islets-human MAPC 
composites, possibly via the promotion of graft revascularization mediated by human MAPC. 
In the near future, we hope it will be possible to reach long-term islet transplant outcomes by 
implementing and combining our approaches avoiding not only the immunological issues of 
islet cell transplantation but also improving islet engraftment.  
 
 
Figure 6.1. Potential benefits of MAPC® and tolerance induction therapy in islet cell transplantation in T1D 
patients. 
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We believe that a combination of approaches will be needed to improve islet transplant 
outcomes, as beta-cell replacement by islet transplantations is confronted with multiples 
hurdles. The use of anti-inflammatory agents, immune modulation without induction of 
homeostatic proliferation, antigen-specific and stem cell therapies need to be further 
investigated. In addition, some questions remain: When to transplant? Where to transplant? 
Which patient population to select? 
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In type 1 diabetic (T1D) patients, the pancreatic insulin-producing beta cells are selectively 
destroyed by the immune system, leading to an impaired glucose metabolism. The steep 
increase in the incidence of this chronic autoimmune pathology especially in young children in 
the last decades raises serious concerns. To date, insulin therapy is considered the gold standard 
for the treatment of T1D. Nevertheless, limitations persist, such as the frequent episodes of 
hypoglycemia, and the chronic micro- and macrovascular complications. Islet cell 
transplantation offers an alternative treatment for T1D patients, specifically for those with 
hypoglycemic unawareness following insulin administration. Despite the improved outcome of 
islet cell transplantation over the last few years, drawbacks remain, such as a limited supply of 
cadaveric donors, the necessity of several donors for a single transplantation, and (immediate) 
graft failure through metabolic pressure, continued autoimmunity, alloimmunity, high 
concentrations of immunosuppressive drugs, and oxidative stress caused by hypoxia or due to 
cytokine exposure. In this PhD thesis, we propose that in the long term, tolerogenic antigen-
based and beta-cell replacement/regenerative approaches could be promising in both blocking 
the autoimmunity to prevent continued beta-cell destruction and boosting beta-cell function and 
revascularization to restore sustainable insulin regulation. 
 
Contrasting with alloimmune responses, autoimmune disease recurrence is difficult to control 
with standard immunosuppression and therefore poses a challenging obstacle for a successful 
long-term islet cell transplantation outcome. In chapter 4, we used a combination therapy 
consisting of a short induction therapy of low doses of anti-CD3 mAbs combined with the 
intragastric delivery of genetically-modified L. lactis-based vaccines producing human 
proinsulin along with pro-tolerogenic IL10 to reestablish tolerance to islet antigens in 
longstanding diabetic NOD islet recipients. We first demonstrate that an early regimen (starting 
5 days before islet implantation) with low-dose anti-CD3 combined or not with L. lactis-based 
antigen-specific therapy induced poor graft acceptance in around 20% of NOD islet recipients. 
However, when therapeutic regimen started at the time of islet implantation, the overall graft 
acceptance was around 56% in L. lactis-based therapy-treated NOD islet recipients. Next, we 
observed that diabetes duration before islet implantation impacts on the rate of success. The 
efficiency to prevent autoimmune diabetes recurrence markedly decreased in anti-CD3-treated 
mice with diabetes duration, while L. lactis-based combination therapy-treated mice were much 
less influenced by this parameter. The efficiency of glycemic control and the rate of graft 
acceptance in relation to the timing of diabetes diagnosis is in part related to the protection of 
residual endogenous islets in the pancreas as reflected by the insulin content of the native 
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pancreas at different time points after diabetes diagnosis. Further, we found that NOD islet 
recipients treated with anti-CD3 alone or combined with the L. lactis-based vaccine had Foxp3+ 
Tregs present in the lymph nodes draining the islet implantation site (i.e. kidney), but this was 
not different between mono- and combination therapy and independent of diabetes duration. 
Based on these observations, we concluded that a mild lymphodepletion with low-dose anti-
CD3 mAbs in combination with an antigen-specific approach using genetically-modified L. 
lactis can by-pass autoimmune diabetes recurrence in 56% of syngeneic islets transplanted in 
longstanding diabetic NOD mice. Moreover, we found that islet cell transplantation outcome 
will certainly depend on the time of islet implantation in relation to T-cell-targeting strategy 
and on the time of islet implantation after diabetes diagnosis. Integration of these antigen-
specific technologies to enhance engraftment and combat graft destruction may help to advance 
the therapeutic efficacy and availability of islet cell transplantation in selected patient 
populations. 
 
In the first days following transplantation, islets lack an adequate vascular network, leading to 
severe hypoxia and cell death. It is believed that this is one of the major causes of the poor 
performance of islet grafts longterm. Thus, in chapter 5 we used a novel class of progenitor 
cells MAPC® and co-transplanted these with mouse islets to improve islet engraftment. First, 
we demonstrated that human MAPC produce high amounts of angiogenic growth factors, 
including VEGF, in vitro and in vivo, as demonstrated by the induction of neoangiogenesis in 
the CAM assay. Next, we showed for the first time that human MAPC co-transplanted as 
composite pellets with mouse islets can improve islet graft function in a syngeneic marginal 
mass islet cell transplantation model as measured by the initial glycemic control, diabetes 
reversal rate, glucose tolerance, and serum C-peptide concentration compared with 
transplantation of islets alone. Moreover, we found that grafts composed of islet-human MAPC 
composites had an improved revascularization process. We found a significant improvement in 
the development of a new islet capillary network in mice where islets were co-transplanted with 
human MAPC. Indeed, higher numbers of capillary-like structures with a lining of endothelial 
cells were found on the periphery and in the intra-islet space of the islet-human MAPC 
composites at week 5 post-transplantation, suggesting that host-derived vessels are directly 
feeding transplanted islets and that close proximity and even direct contact between the 
transplanted pancreatic islets and human MAPC is of critical importance for the improved 
glucose control, diabetes reversal rate and increased revascularization. The present data propose 
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that co-transplantation of mouse pancreatic islets with human MAPC, which secrete high 
amounts of angiogenic growth factors, enhance islet graft revascularization and subsequently 
improve islet graft function.  
 
As a general conclusion, the data presented in this PhD thesis show promising therapeutic 
approaches to improve islet transplant outcomes. Our work also indicates that these approaches 
should act on different levels to overcome the many hurdles of beta-cell replacement in the 
modality of islet cell transplantation. We showed that genetically-modified L. lactis-based 
antigen-specific vaccines combined with a short course of low doses of anti-CD3 mAbs can 
avoid autoimmune diabetes recurrence depending on the time of islet implantation in relation 
to T-cell-targeting strategy and on the time of islet implantation after diabetes diagnosis. We 
also showed that the use of human MAPC in islet cell transplantation can improve islet graft 
morphology and function by transplantation of islets-human MAPC composites, possibly via 
the promotion of graft revascularization mediated by human MAPC. In the near future, we hope 
it will be possible to reach long-term islet transplant outcomes by implementing and combining 
our approaches avoiding not only the immunological issues of islet cell transplantation but also 
improving islet engraftment. 
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In type 1 diabetes (T1D) worden de insulineproducerende beta cellen in de pancreas selectief 
vernietigd door het immuunsysteem, wat leidt tot een gebrekkig glucosemetabolisme. De sterke 
toename in de incidentie van deze chronische autopathologie vooral tijdens de laatste decennia 
en in jonge kinderen, is aanleiding tot ernstige bezorgdheid. Tot op heden wordt 
insulinetherapie beschouwd als de gouden standaard in de behandeling van T1D. Toch zijn er 
nog altijd beperkingen zoals de frequente episoden van hypoglycemie en de chronische micro- 
en macrovasculaire complicaties. Eilandjestransplantatie biedt een alternatieve behandeling 
voor T1D patiënten, in het bijzonder voor mensen met hypo-onbewustheid na toediening van 
insuline. Ondanks dat de resultaten van eilandjestransplantatie de afgelopen jaren sterk 
verbeterd zijn blijven er nadelen, zoals een beperkt aanbod aan postmortale donoren, de 
noodzaak van verschillende donoren voor één transplantatie, en (direct) transplantfalen door 
metabolische druk, aanhoudende alloimmuniteit, noodzaak om hoge concentraties 
immunosuppressieve geneesmiddelen te gebruiken en oxidatieve stress veroorzaakt door 
hypoxie of door blootstelling aan proinflammatoire cytokinen. In dit proefschrift willen we 
onderzoeken of een autoantigeen-gebaseerde en beta-celvervangende/regeneratieve aanpak de 
resultaten van eilandjestransplantatie in T1D kan verbeteren. We vermoeden dat onze aanpak 
kan leiden tot het blokkeren van de autoimmuniteit en dus beta-celvernietiging kan voorkomen, 
alsook de functie en revascularisatie van eilandjestransplant kan stimuleren waardoor de 
insulinewerking blijvend kan herstellen. 
 
In tegenstelling tot alloimmuniteit is het heroptreden van autoimmune diabetes na 
eilandjestransplantatie moeilijk te controleren met standaard immunosuppressie, en vormt dit 
een uitdagende hindernis voor een succesvolle eilandjestransplantatie. In hoofdstuk 4 hebben 
we gebruik gemaakt van een combinatietherapie bestaande uit een korte inductietherapie met 
lage dosis anti-CD3 mAb in combinatie met toediening van tolerogene genetisch 
gemodificeerde L. lactis-gebaseerde vaccins die menselijke pro-insuline produceren, tesamen 
met IL10, om tolerantie voor eilandjesantigenen te herstellen in langdurig diabete NOD 
eilandjesrecipiënten. Ten eerste tonen we aan dat een vroege behandeling (vanaf 5 dagen vóór 
eilandjesimplantatie) met lage dosis anti-CD3, al dan niet gecombineerd met L. lactis-
gebaseerde antigeenspecifieke behandeling, een transplant-acceptatie induceerde in amper 20% 
van NOD eilandjesrecipiënten. Wanneer echter de L. lactis-gebaseerde combinatietherapie 
gestart werd op het moment van de eilandjesimplantatie zagen we eilandjes acceptatie in 56% 
van de NOD recipiënten. Vervolgens stelden we vast dat de duur van diabetes voor het moment 
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van transplantatie gevolgen had voor het acceptatie percentage. De efficiëntie om heroptreden 
van autoimmune diabetes te voorkomen verminderde zichtbaar met diabetesduur in anti-CD3-
behandelde muizen, terwijl muizen behandeld met L. lactis-gebaseerde combinatietherapie veel 
minder beïnvloed werden door deze parameter. De efficiëntie om diabetes onder controle te 
krijgen en de snelheid van transplant-acceptatie bleek in verhouding te zijn met de diabetesduur. 
In muizen met een korte diabetesduur was er een duidelijk therapeutic effect waar te nemen op 
de overblijvende endogene eilandjes in de pancreas, terwijl in muizen met langdurige diabetes 
er meestal geen endogene beta-celmassa overbleef om nog te beschermen. Verder vonden we 
dat NOD eilandjesrecipiënten behandeld met anti-CD3 alleen of gecombineerd met het L. 
lactis-gebaseerde vaccin Foxp3+, regulatoire T cellen (Treg) hadden in de lymfeknopen die de 
eilandjesimplantatieplaats (de nier) draineren maar dit was niet verschillend tussen de mono- 
en combinatietherapie en onafhankelijk van de diabetesduur. Gebaseerd op deze waarnemingen 
concluderen we dat een milde lymfodepletie met een lage dosis anti-CD3 mAb in combinatie 
met de antigeen-specifieke aanpak van genetisch gemodificeerde L. lactis bacteriën, het 
heroptreden van autoimmune diabetes kan omzeilen in 56% van langdurige diabetische NOD 
muizen met syngene eilandjes getransplanteerd. Bovendien toonden we aan dat het resultaat 
van de eilandjestransplantatie sterk afhankelijk is van het tijdspunt van eilandjesimplantatie met 
betrekking tot T-cel-targetingstrategie en tot de diabetesduur. De integratie van deze tolerogene 
antigeen-specifieke technologie om het transplant te versterken en transplantvernietiging te 
bestrijden kan de resultaten van eilandjestransplantatie in geselecteerde patiëntenpopulaties 
verbeteren. 
 
In de eerste dagen na transplantatie ontbreekt een adequaat vasculair network in de eilandjes, 
wat leidt tot ernstige hypoxie en celdood. Men gelooft dat dit één van de belangrijkste oorzaken 
is voor de slechte prestaties van eilandjestransplanten onmiddellijk na implantatie. Daarom 
hebben we in hoofdstuk 5 een nieuwe klasse van progenitorcellen MAPC® gebruikt en deze 
ge-cotransplanteerd met muiseilandjes om de resultaten van de transplantatie te bevorderen. 
Ten eerste hebben we aangetoond dat menselijke MAPC grote hoeveelheden angiogene 
groeifactoren (bv. VEGF) produceren in vivo en in vitro, wat o.a. blijkt uit de inductie van neo-
angiogenese in de CAM assay. Vervolgens toonden we voor de eerste keer aan dat de 
menselijke MAPC co-getransplanteerd als samengestelde pellets met de muiseilandjes de 
eilandjestransplantfunctie kon verbeteren in een syngeen “marginale massa” 
eilandjestransplantatiemodel zoals gemeten kon worden aan de snelheid van diabetescontrole 
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en functionalitiet van de eilandjes vergeleken met een transplantatie van eilandjes alleen. 
Bovendien stelden we vast dat transplanten samengesteld uit muiseilandjes opgemengd met 
menselijke MAPC een verbeterd revascularisatieproces hadden. In de transplanten van muizen 
waarin eilandjes tesamen met menselijke MAPC werden getransplanteerd was er een duidelijke 
verbetering in de ontwikkeling van een nieuw capillair network. Een grotere hoeveelheid 
capillair-achtige structuren met een voering van endotheelcellen kon aangetoond worden in de 
periferie en in de eilandjes van de eilandjes-humane MAPC composieten 5 weken na 
implantatie. Dit suggereert dat gastheer-afkomstige bloedvaten rechtstreeks de 
getransplanteerde eilandjes voeden en dat de nabijheid, en zelfs het direct contact tussen de 
getransplanteerde eilandjes en de menselijke MAPC, van cruciaal belang is voor de verbetering 
van diabetescontrole en de verhoogde revascularisatie. Op basis van deze gegevens stellen wij 
voor dat een co-transplantatie van pancreaseilandjes tesamen met MAPC, welke hoge 
concentraties aan angiogene groeifactoren kunnen afscheiden, de eilandjestransplant-
revascularisatie kunnen verbeteren en dus ook de eilandjestransplant-functie bevorderen. 
 
Als algemene conclusie stellen we voor dat de bevindingen in dit proefschrift kunnen leiden tot 
nieuwe veelbelovende therapieën die de resultaten van eilandjestransplantatie kunnen 
verbeteren. Ons werk geeft ook aan dat deze therapieeën moeten inwerken op verschillende 
niveaus om de vele hindernissen van beta-celvervanging door middel van 
eilandjestransplantatie te overwinnen. We toonden aan dat genetisch gemodificeerde L. lactis-
gebaseerde antigeenspecifieke vaccins, gecombineerd met een korte behandeling bestaande uit 
lage dossisen anti-CD3, het heroptreden van autoimmmune diabetes na eilandjestransplantatie 
kunnen voorkomen afhankelijk van het tijdstip van eilandjesimplantatie met betrekking tot T-
cel-targetingstrategie en tot diabetesduur. We toonden ook aan dat het gebruik van menselijke 
MAPC in eilandjestransplantatie de transplantmorfologie alsook de functie ervan kan 
verbeteren door deze tesamen als composieten te transplanteren. We hebben voldoende 
bewijzen om aan te nemen dat dit gebeurt via het bevorderen van transplant-revascularisatie 
gemediëerd door de menselijke MAPC. We hopen dat het in de nabije toekomst mogelijk zal 
zijn om de langetermijn resultaten van eilandjestransplantatie te verbeteren door het 
implementeren en het combineren van onze vernieuwende therapieën. Onze aanpak zou zowel 
de immunologische problemen alsook de moeizame revascularizatie na eilandjestransplantatie 
kunnen oplossen. 
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- III International Symposium of Cellular Therapy, 2008. 
- 28th Congress of Brazilian Association of Veterinary Clinicians of Small Animal, 2007. 
 
Pre-reviewed journal articles  
- Vangoitsenhoven R., van der Ende M., Cunha J.P.M.CM., Corbeels K., Lannoo M., 
Bedossa P., van der Merwe S., Mertens A., Gesquiere I., Meulemans A., Matthys C., 
Mathieu C., Overbergh L., Van der Schueren B. (2016) Dietary composition determines the 
degree of metabolic improvement at similar weight loss. Submitted  
 
- Cunha J.P.M.C.M., Leuckx G., Sterkendries P., Korf H., Bomfim-Ferreira G., Overbergh 
L., Vaes B., Heimberg H., Gysemans C., Mathieu C. (2017) Human Multipotent Adult 
Progenitor Cells Enhance Islet Function And Revascularization When Co-Transplanted As 
A Composite Pellet In A Mouse Model Of Diabetes. Diabetologia  60:134-142  
 
- Cunha J.P.M.C.M., Gysemans C., Gillard P., Mathieu C. (2016) Stem-Cell-Based 
Therapies for Improving Islet cell transplantation Outcomes in Type 1 Diabetes. Current 
Diabetes Review (in press) 
 
- M.G.M.C.M. Cunha, Raiser A.G., Martins D.B., Lopes S.T.A., Freitas G.C., Beckmann 
D.V., Cunha J.P.M.C.M., Teixeira L.V., Pippi N.L. (2016). Fluid therapy rate in postrenal 
azotemia stabilization in cats. Symbiosis Journal of Veterinary Science (in press) 
 
- Ferreira G.B., Gysemans C.A., Demengeot J.,  Cunha J.P.M.C.M., Vanherwegen A.S., 
Overbergh L, Van Belle T.L., Pauwels F., Verstuyf A., Korf H., Mathieu C. (2014). 1,25-
Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory 
properties in NOD mice. The Journal of Immunology 192:4210-4220.  
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- Freitas, G.C., Cunha, M.G.M.C.M., Carregaro, A.B., Gomes, K., Cunha, J.P.M.C.M., 
Tognini, M., Pippi, N.L. (2012). Acid-base and biochemical stabilization and quality of 
recovery in male cats with urethral obstruction and anesthetized with propofol or a 
combination of ketamine and diazepam. Canadian Journal of Veterinary Research 
76:201-208. 
 
- Maris, M., Overbergh, L., Gysemans, C., Waget, A., Cardozo, A.K., Verdrengh E., Cunha, 
M.C.M.J.P., Gotoh, T., Cnop, M., Eizirik, D.L., Burcelin, R., Mathieu, C. (2012). Deletion 
of C/EBP homologous protein (Chop) in C57Bl/6 mice dissociates obesity from insulin 
resistance. Diabetologia 55:1167-1178.  
 
- Treichel, T. E., Cunha, M. G. M. C. M., Cunha, J. P. M. C. M., Pippi, N. L., Lopes, S. T. 
A., Santos Junior, E. B., Fighera, R. A., Rosa, M. B. (2011). Total fraction of mononuclear 
cell or stromal vascular fraction transplant associated with cellulosic membrane in 
experimental cutaneous wounds in rabbits. Brazilian Journal of Veterinary Research and 
Animal Science (Impresso) 48:62-72 
 
- Müller, D. C.M., Basso, P.C., Serafine, G.M. C.., Rosa, M.B., Sprada, A.G., Cunha, 
J.P.M.C.M.; Pippi, N.L. (2011). Replacement of the cranial and caudal cruciate ligaments 
in dogs by double t polypropylene implant. Ciência Rural (UFSM) 41:487-491 
 
- Cunha, M.G.M.C.M., Freitas, G.C., Carregaro, A.B., Gomes, K., Cunha, J.P.M.C.M., 
Beckmann, D.V., Pippi, N.L. (2010) Renal and cardiorespiratory effects of treatment with 
lactated Ringer's solution or physiologic saline (0.9% NaCl) solution in cats with 
experimentally induced urethral obstruction. American Journal of Veterinary Research. 
71:840-846.  
 
- Cunha, M.G.M.C..M., Pippi. N.L., Gomes. K., Cunha, J.P.M.C.M. (2010). Cerclage with 
Nylon Cable Tie Band or Stainless Steel Wire for Repair of Experimental Mandibular 
Symphyseal Fractures in Cat. Acta Scientiae Veterinariae. 38:363-369. 
 
- Cunha, M.G.M.C.M., Gomes, K., Cunha, J.P.M.C.M., Pippi, N.L., Rappeti, J.C. (2009). 
Catheter needle for osteosynthesis of the rib in a dog. Acta Scientiae Veterinariae. 37:205-
209. 
 
Oral Presentation and Poster presented during PhD 
- Cunha JPMCM, Leuckx G, Sterkendries P, Korf H, Ferreira GB, Vaes B, Heimberg H, 
Gysemans C Mathieu C. Human multipotent adult progenitor cells enhance islet 
function and revascularization when co-transplanted as a composite pellet in a mouse 
model of diabetes 25th meeting of the Belgian Endocrine Society. Antwerp, Belgium, 
October 23-24, 2015. Award best poster. 
 
- Cunha JPMCM, Leuckx G, Sterkendries P, Korf H, Ferreira GB, Vaes B, Heimberg H, 
Gysemans C Mathieu C. Improved islet function and revascularization by co-
transplantation of human multipotent adult progenitor cells in diabetes mouse model 
European Society for Organ Transplantation Congress, Brussels, Belgium, September 13-
16, 2015. 
 
- Cunha JPMCM, Leuckx G, Sterkendries P, Korf H, Ferreira GB, Vaes B, Heimberg H, 
Gysemans C Mathieu C. Human multipotent adult progenitor cells enhance islet 
function and revascularization when co-transplanted in a mouse model of diabetes. 
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Poster presentation at the Islet Study Group & Beta Cell Workshop, Jerusalem, Israel, May 
3-7, 2015. Award with a scholarship which covered registration fees and cost of 
accommodation.  
 
- Cunha JPMCM, Leuckx G, Sterkendries P, Korf H, Ferreira GB, Vaes B, Heimberg H, 
Gysemans C Mathieu C. Human multipotent adult progenitor cells enhance islet 
function and revascularization when co-transplanted in a mouse model of diabetes. 
Poster and oral presentation at the Belgian Diabetes Excellence Summit, Brussels, Belgium, 
April 25, 2015. Award and oral presentation. 
 
- Cunha JPMCM, Takiishi T, Belle T, Korf H, Rottiers P, Steidler L, Gysemans C, Mathieu 
C. Antigen-specific therapy with human proinsulin and IL10 in combination with 
short-course monoclonal CD3 antibody in preclinical models of islet transplant Poster 
presentation at the World Transplantation Congress, San Francisco, USA, July 26-31, 2014. 
Poster distinction after review in the top 20% of the topic. 
 
Knowledge of foreign languages 
Understands: English (Fluent), Portuguese (Fluent), Spanish (Functional) 
Speaks: English (Fluent), Portuguese (Fluent), Spanish (Functional) 
Reads: English (Fluent), Portuguese (Fluent), Spanish (Functional) 
Writes: English (Fluent), Portuguese (Fluent), Spanish (Functional) 
